<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00928434</url>
  </required_header>
  <id_info>
    <org_study_id>FE200486 CS37</org_study_id>
    <nct_id>NCT00928434</nct_id>
  </id_info>
  <brief_title>A Study of Degarelix in Patients With Prostate Cancer</brief_title>
  <official_title>A Randomized, Controlled, Open-Label Study Investigating the Safety and Efficacy of Degarelix Given Intermittently vs Continuous Androgen Deprivation Therapy With Lupron or Degarelix in Patients With Prostate Cancer With Prior Treatment Failure After Localized Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ferring Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to see if giving Degarelix every month for 7 months then stop
      treatment for 7 months (intermittent therapy) would show a reduction of negative effects of
      androgen deprivation therapy by increasing the quality of life while keeping prostate
      specific antigen (PSA) levels suppressed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was an open-label, randomized, parallel-arm, multicenter study to determine if degarelix
      intermittent therapy was non-inferior to continuous androgen deprivation therapy (combination
      of treatment groups receiving continuous degarelix and leuprolide therapy, respectively) in
      maintaining PSA levels at ≤ 4.0 ng/mL at 14 months.

      The study consisted of two phases, Phase A and B. During Phase A, patients in the degarelix
      intermittent and degarelix continuous arms received 7 months of therapy with degarelix
      one-month depot formulation and patients in the leuprolide continuous arm received leuprolide
      one-month depot injection (7.5 mg) followed by two 3-month depot (22.5 mg) injections. After
      7 months of treatment, patients with a PSA ≤2 ng/mL continued into Phase B.

      During Phase B, patients in the degarelix intermittent arm had a 7-month off-treatment
      period. Patients randomized to the degarelix continuous arm and the leuprolide continuous arm
      continued to receive degarelix or leuprolide depot as in Phase A for the remainder of the 14
      months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Patients With Serum PSA Levels ≤4.0 ng/mL</measure>
    <time_frame>At 14 month</time_frame>
    <description>Percentage of patients with serum PSA levels ≤4.0 ng/mL at 14 month was presented.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in Serum PSA Levels</measure>
    <time_frame>Phase A Visit 1-8 and Phase B Visit 9-15.</time_frame>
    <description>Absolute change from Baseline in serum PSA levels during the study period was measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Serum PSA Levels</measure>
    <time_frame>Phase A Visit 1-8 and Phase B Visit 9-15.</time_frame>
    <description>Percent change from Baseline in serum PSA levels during the study period was measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Quality of Life as Assessed by the Functional Assessment of Cancer Therapy-Prostate (FACT-P) : Physical Well-being</measure>
    <time_frame>During 14 months</time_frame>
    <description>The FACT-P is a multidimensional, self-report quality of life (QoL) instrument specifically designed for use with prostate cancer patients. It consists of 27 core items which assess patient function in four domains: Physical, Social/Family, Emotional, and Functional well-being, which is further supplemented by 12 site specific items to assess for prostate related symptoms. Each question is rated on a scale from 0 to 4, and then combined to produce sub-scale scores for each domain, as well as a global QoL score.
Physical well-being consist of 7 items and scored on a scale of 0-4 (0=Not at all; 1=A little bit; 2=Somewhat; 3=Quite a bit; 4=Very much). Total score for the physical well-being sub scale ranges from 0 to 28. Higher scores represent better QoL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Quality of Life as Assessed by the FACT-P : Emotional Well-being</measure>
    <time_frame>During 14 months</time_frame>
    <description>The FACT-P is a multidimensional, self-report quality of life (QoL) instrument specifically designed for use with prostate cancer patients. It consists of 27 core items which assess patient function in four domains: Physical, Social/Family, Emotional, and Functional well-being, which is further supplemented by 12 site specific items to assess for prostate related symptoms. Each question is rated on a scale from 0 to 4, and then combined to produce sub-scale scores for each domain, as well as a global QoL score.
Emotional well-being consist of 6 items and scored on a scale of 0-4 (0=Not at all; 1=A little bit; 2=Somewhat; 3=Quite a bit; 4=Very much). Total score for the emotional well-being sub scale ranges from 0 to 24. Higher scores represent better QoL.Higher scores represent better QoL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Quality of Life as Assessed by the FACT-P : Social Well-being</measure>
    <time_frame>During 14 months</time_frame>
    <description>The FACT-P is a multidimensional, self-report quality of life (QoL) instrument specifically designed for use with prostate cancer patients. It consists of 27 core items which assess patient function in four domains: Physical, Social/Family, Emotional, and Functional well-being, which is further supplemented by 12 site specific items to assess for prostate related symptoms. Each question is rated on a scale from 0 to 4, and then combined to produce sub-scale scores for each domain, as well as a global QoL score.
Social well-being consist of 7 items and scored on a scale of 0-4 (0=Not at all; 1=A little bit; 2=Somewhat; 3=Quite a bit; 4=Very much). Total score for the social well-being sub scale ranges from 0 to 28. Higher scores represent better QoL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Quality of Life as Assessed by the FACT-P : Functional Well-being</measure>
    <time_frame>During 14 months</time_frame>
    <description>The FACT-P is a multidimensional, self-report quality of life (QoL) instrument specifically designed for use with prostate cancer patients. It consists of 27 core items which assess patient function in four domains: Physical, Social/Family, Emotional, and Functional well-being, which is further supplemented by 12 site specific items to assess for prostate related symptoms. Each question is rated on a scale from 0 to 4, and then combined to produce sub-scale scores for each domain, as well as a global QoL score.
Functional well-being consist of 7 items and scored on a scale of 0-4 (0=Not at all; 1=A little bit; 2=Somewhat; 3=Quite a bit; 4=Very much). Total score for the functional well-being sub scale ranges from 0 to 28. Higher scores represent better QoL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Quality of Life as Assessed by the FACT-P : Additional Concerns</measure>
    <time_frame>During 14 months</time_frame>
    <description>The FACT-P is a multidimensional, self-report quality of life (QoL) instrument specifically designed for use with prostate cancer patients. It consists of 27 core items which assess patient function in four domains: Physical, Social/Family, Emotional, and Functional well-being, which is further supplemented by 12 site specific items to assess for prostate related symptoms. Each question is rated on a scale from 0 to 4, and then combined to produce sub-scale scores for each domain, as well as a global QoL score.
Additional concerns consist of 12 items and scored on a scale of 0-4 (0=Not at all; 1=A little bit; 2=Somewhat; 3=Quite a bit; 4=Very much). Total score for the additional concerns ranges from 0 to 48. Higher scores represent better QoL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Quality of Life as Assessed by the FACT-P: Total FACT-P Score</measure>
    <time_frame>During 14 months</time_frame>
    <description>The FACT-P is a multidimensional, self-report quality of life (QoL) instrument specifically designed for use with prostate cancer patients. It consists of 27 core items which assess patient function in four domains: Physical, Social/Family, Emotional, and Functional well-being, which is further supplemented by 12 site specific items to assess for prostate related symptoms. Each question is rated on a scale from 0 to 4, and then combined to produce sub-scale scores for each domain, as well as a global QoL score. Total FACT-P scores ranges from 0 to 156. Higher scores represent better QoL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Sexual Function as Assessed by the Sexual Function Index (SFI): Sexual Drive</measure>
    <time_frame>During 14 months</time_frame>
    <description>The SFI is a multidimensional, self-report instrument specifically designed to evaluate sexual function and satisfaction of men on treatment or with conditions that may affect sexual function. It consists of 11 questions which assess patient function in four domains: Sexual drive, Erection, Ejaculation, and Problem assessment, and a question in regards to overall assessment of sexual function.
Sexual drive domain consist of 2 questions and are scored on a scale of 0-4 (0=minimum, 4=maximum). Total score for the sexual drive domain ranges from 0 to 8. A higher scores represent better sexual function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Sexual Function as Assessed by the SFI: Erection</measure>
    <time_frame>During 14 months</time_frame>
    <description>The SFI is a multidimensional, self-report instrument specifically designed to evaluate sexual function and satisfaction of men on treatment or with conditions that may affect sexual function. It consists of 11 questions which assess patient function in four domains: Sexual drive, Erection, Ejaculation, and Problem assessment, and a question in regards to overall assessment of sexual function.
Erection domain consist of 3 questions and are scored on a scale of 0-4 (0=minimum, 4=maximum). Total score for the erection domain ranges from 0 to 12. A higher scores represent better sexual function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Sexual Function as Assessed by the SFI: Ejaculation</measure>
    <time_frame>During 14 months</time_frame>
    <description>The SFI is a multidimensional, self-report instrument specifically designed to evaluate sexual function and satisfaction of men on treatment or with conditions that may affect sexual function. It consists of 11 questions which assess patient function in four domains: Sexual drive, Erection, Ejaculation, and Problem assessment, and a question in regards to overall assessment of sexual function.
Ejaculation domain consist of 2 questions and are scored on a scale of 0-4 (0=minimum, 4=maximum). Total score for the ejaculation domain ranges from 0 to 8. A higher scores represent better sexual function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Sexual Function as Assessed by the SFI: Problem Assessment</measure>
    <time_frame>During 14 months</time_frame>
    <description>The SFI is a multidimensional, self-report instrument specifically designed to evaluate sexual function and satisfaction of men on treatment or with conditions that may affect sexual function. It consists of 11 questions which assess patient function in four domains: Sexual drive, Erection, Ejaculation, and Problem assessment, and a question in regards to overall assessment of sexual function.
Problem assessment domain consist of 2 questions and are scored on a scale of 0-4 (0=minimum, 4=maximum). Total score for the problem assessment domain ranges from 0 to 8. A higher scores represent better sexual function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Sexual Function as Assessed by the SFI: Overall Satisfaction With Sex Life</measure>
    <time_frame>During 14 months</time_frame>
    <description>The SFI is a multidimensional, self-report instrument specifically designed to evaluate sexual function and satisfaction of men on treatment or with conditions that may affect sexual function. It consists of 11 questions which assess patient function in four domains: Sexual drive, Erection, Ejaculation, and Problem assessment, and a question in regards to overall assessment of sexual function.
Overall satisfaction domain consist of single question and is scored on a scale of 0-4 (0=minimum, 4=maximum). A higher score represent better sexual function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Sexual Function as Assessed by the SFI: Total SFI Score</measure>
    <time_frame>During 14 months</time_frame>
    <description>The SFI is a multidimensional, self-report instrument specifically designed to evaluate sexual function and satisfaction of men on treatment or with conditions that may affect sexual function. It consists of 11 questions which assess patient function in four domains: Sexual drive, Erection, Ejaculation, and Problem assessment, and a question in regards to overall assessment of sexual function. Total SFI score ranges from 0 to 44. A higher scores represent better sexual function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With a Serum PSA Level ≤4.0 ng/mL</measure>
    <time_frame>At 14 months</time_frame>
    <description>Percentage of Subjects With a Serum PSA Level ≤4.0 ng/mL was measured during the study period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Return to Testosterone &gt;0.5 ng/mL Level in the DI Treatment Group</measure>
    <time_frame>During Phase B</time_frame>
    <description>The time to testosterone &gt;0.5 ng/mL level in the DI group was counted from the start of Phase B at Day 196 (i.e. 28 days after last injection of degarelix)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Return to Normal Range (≥1.5 ng/mL) or Baseline Testosterone Level</measure>
    <time_frame>During Phase B</time_frame>
    <description>The time to return to normal range (≥1.5 ng/mL) or Baseline testosterone level in the DI group was counted from the start of Phase B at Day 196 (i.e. 28 days after last injection of degarelix).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in Serum Testosterone Levels</measure>
    <time_frame>Phase A Visit 1-8 and Phase B Visit 9-15.</time_frame>
    <description>Absolute Change From Baseline in Serum Testosterone Levels was measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Serum Testosterone Levels</measure>
    <time_frame>Phase A Visit 1-8 and Phase B Visit 9-15.</time_frame>
    <description>Percent change from Baseline in serum testosterone levels was measured.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">409</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>DI (Degarelix Intermittent)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this arm received degarelix with a starting dose of 240 mg at a concentration of 40 mg/mL on Day 0 administered subcutaneously (s.c.) into the anterior abdominal wall via two equivalent injections of 120 mg (3 mL) each.
Six maintenance doses of degarelix 80 mg per month at a concentration of 20 mg/mL (4 mL) at Days 28 to 168 were administered.
During Phase B of the trial, If a patient had Prostate Specific Antigen (PSA) ≥2 ng/mL at any visit, additional doses of degarelix 240 mg followed by 80 mg maintenance dose(s) were administered.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DC (Degarelix Continuous)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this arm received degarelix with a starting dose of 240 mg at a concentration of 40 mg/mL administered on Day 0 (Visit 1) s.c. into the anterior abdominal wall via two equivalent injections of 120 mg (3 mL) each.
Thirteen maintenance doses of degarelix 80 mg per month at a concentration of 20 mg/mL (4 mL) at Days 28 to 364, administered s.c. into the anterior abdominal wall</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LC (Leuprolide Continuous)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this arm received leuprolide 7.5 mg one-month depot injection on Day 0, administered intramuscular (i.m.) into a large muscle, as per manufacturer's labeling directions.
One injection of 22.5 mg leuprolide 3-month depot was administered i.m. as per manufacturer's labeling directions at Day 28 and every 3 months afterwards for 4 additional doses (i.e at Days 112, 196, 280, and 364, respectively).
On Investigator's discretion, patients in the arm could take bicalutamide (Casodex®) for a maximum of 28 days to alleviate increased signs and symptoms due to initial upsurge in testosterone levels.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Degarelix</intervention_name>
    <description>Degarelix treatment provided for first seven months (one starting dose and six maintenance doses) followed by no treatment for next seven months period.</description>
    <arm_group_label>DI (Degarelix Intermittent)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Degarelix</intervention_name>
    <description>Degarelix treatment provided for complete study period (one starting dose and 13 maintenance doses).</description>
    <arm_group_label>DC (Degarelix Continuous)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leuprolide</intervention_name>
    <description>Leuprolide treatment for complete study period (one starting dose and 5 maintenance doses of 3-month depot each)</description>
    <arm_group_label>LC (Leuprolide Continuous)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years or older.

          -  Raising PSA after prior treatment failure of localized prostate cancer.

          -  Has a histological confirmed non-metastatic cancer of the prostate (Gleason graded)
             based on the most current biopsy.

          -  Has a screening testosterone within normal range (≥1.5 ng/mL).

          -  Has Eastern Cooperative Oncology Group score of ≤2.

          -  Bone scan or CT scan report documenting no evidence of metastasis to the bone or
             internal organs.

          -  Life expectancy of at least 15 months.

        Exclusion Criteria:

          -  Taken hormone therapy in the last 6 months prior to entering this study.

          -  Being treated with 5-alpha reductase inhibitor at time of enrolment and remained on a
             stable dose throughout the trial.

          -  Has a history of severe uncontrolled asthma, anaphylactic reactions, or severe
             urticaria and/or angioedema.

          -  Has hypersensitivity towards any component of the study drug.

          -  Has a previous history or presence of another malignancy other than prostate cancer or
             treated squamous/basal cell carcinoma of the skin within the last five years.

          -  Has abnormal laboratory results which in the judgement of the Investigator would
             affect the patient's health or the outcome of the trial.

          -  Has a clinically significant medical condition (other than prostate cancer) including
             but not limited to; renal, haematological, gastrointestinal, endocrine, cardiac,
             neurological or psychiatric disease and alcohol or drug abuse or any other condition
             which may affect the patient's health or the outcome of the trial as judged by the
             Investigator.

          -  Has an intellectual incapacity or language barriers precluding adequate understanding
             or co-operation.

          -  Has received an investigational drug within the last 28 days before the Screening
             visit or longer if considered to possibly influence the outcome of the current trial.

          -  Has received ketoconazole or diflucan in the last 28 days preceding the Screening
             Visit.

          -  Has previously participated in any Degarelix trial.

          -  Is part of an ongoing trial.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Development Support</last_name>
    <role>Study Director</role>
    <affiliation>Ferring Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alabama Clinical Research, Inc</name>
      <address>
        <city>Alexander City</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology Center of Alabama, PC</name>
      <address>
        <city>Homewood</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Urology Medical Center</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peninsula Urology Medical Center</name>
      <address>
        <city>Atherton</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology Associates of Central California</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Orange County Medical Research Center</name>
      <address>
        <city>Laguna Hills</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlantic Urology Medical Group</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Bernardino Urological Associates</name>
      <address>
        <city>San Bernardino</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Diego Uro-Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santa Barbara Clinical Research</name>
      <address>
        <city>Santa Barbara</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Health Sciences Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Urology Center of Colorado</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology Associates Research</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connecticut Clinical Research Center</name>
      <address>
        <city>Middlebury</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grove Hill Medical Center</name>
      <address>
        <city>New Britain</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Walter Reed Army Hospital Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Florida Medical Research</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology Health Solutions, Inc</name>
      <address>
        <city>Celebration</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Urology Physicians</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winter Park Urology Associates</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeastern Urology Center, PA</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampa Bay Urology</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Research Institute, Inc</name>
      <address>
        <city>Trinity</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology Enterprises</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Urology/RMD Clinical Research Institute</name>
      <address>
        <city>Melrose Park</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deaconess Clinic Inc</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northeast Indiana Research</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metropolitan Urology, PSC</name>
      <address>
        <city>Jeffersonville</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Urology, Lic</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chesapeake Urology Associates</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chesapeake Urology Research Associates</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chesapeake Urology Research Associates</name>
      <address>
        <city>Glen Burnie</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Myron Murdock M.D. LLC</name>
      <address>
        <city>Greenbelt</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chesapeake Urology Associates, PA</name>
      <address>
        <city>Towson</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology Associates of Englewood</name>
      <address>
        <city>Englewood</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamilton Urology PA</name>
      <address>
        <city>Hamilton</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lawrenceville Urology</name>
      <address>
        <city>Lawrenceville</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nationsmed Clinical Research</name>
      <address>
        <city>Perth Amboy</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Urologic Care</name>
      <address>
        <city>Voorhees</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Delaware Valley Urology LLC</name>
      <address>
        <city>Westampton</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Urological Institute of NE NY, CCP</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical &amp; Clinical Research Associates</name>
      <address>
        <city>Bay Shore</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brooklyn Heights Urology Associates, P.C.</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Urology Associates</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hudson Valley Urology P.C.</name>
      <address>
        <city>Poughkeepsie</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northeast Urology Research</name>
      <address>
        <city>Concord</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alliance Urology Specialists</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urological Association of Lancaster</name>
      <address>
        <city>Lancaster</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State College Urologic Association</name>
      <address>
        <city>State College</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina Urologic Research Center</name>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lexington Urological Associates, PA</name>
      <address>
        <city>West Columbia</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology Associates</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lackland Air Force base</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology of Virginia</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginal Urology</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Urology Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Urology Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roger D. Fincher, PS</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 25, 2009</study_first_submitted>
  <study_first_submitted_qc>June 25, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2009</study_first_posted>
  <results_first_submitted>May 9, 2016</results_first_submitted>
  <results_first_submitted_qc>October 21, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 13, 2016</results_first_posted>
  <disposition_first_submitted>September 20, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>September 20, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 27, 2013</disposition_first_posted>
  <last_update_submitted>October 21, 2016</last_update_submitted>
  <last_update_submitted_qc>October 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leuprolide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Of the total 409 patients enrolled, six patients were not dosed either due to randomisation error, failing eligibility criteria or consent withdrawal after being randomised.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>DI (Degarelix Intermittent)</title>
          <description>Patients in this arm received degarelix with a starting dose of 240 mg at a concentration of 40 mg/mL on Day 0 (Visit 1) administered subcutaneously (s.c.) into the anterior abdominal wall via two equivalent injections of 120 mg (3 mL) each.
Six maintenance doses of degarelix 80 mg per month at a concentration of 20 mg/mL (4 mL) at Days 28 to 168 (Visit 2 through 7), administered s.c. into the anterior abdominal wall
During Phase B of the trial, If a patient had Prostate Specific Antigen (PSA) ≥2 ng/mL at any visit, additional doses of degarelix 240 mg followed by 80 mg maintenance dose(s) were administered.
Degarelix: Degarelix treatment provided for first seven months (one starting dose and six maintenance doses) followed by no treatment for next seven months period.</description>
        </group>
        <group group_id="P2">
          <title>DC (Degarelix Continuous)</title>
          <description>Patients in this arm received degarelix with a starting dose of 240 mg at a concentration of 40 mg/mL administered on Day 0 (Visit 1) s.c. into the anterior abdominal wall via two equivalent injections of 120 mg (3 mL) each.
Thirteen maintenance doses of degarelix 80 mg per month at a concentration of 20 mg/mL (4 mL) at Days 28 to 364, administered s.c. into the anterior abdominal wall
Degarelix: Degarelix treatment provided for complete study period (one starting dose and 13 maintenance doses).</description>
        </group>
        <group group_id="P3">
          <title>LC (Leuprolide Continuous)</title>
          <description>Patients in this arm received leuprolide 7.5 mg one-month depot injection on Day 0 (Visit 1), administered intramuscular (i.m.) into a large muscle, as per manufacturer’s labeling directions.
One injection of 22.5 mg leuprolide 3-month depot was administered i.m. into a large muscle, according to the directions for use in the manufacturer’s labeling at Day 28 and every 3 months afterwards for 4 additional doses (i.e at Days 112, 196, 280, and 364, respectively).
On Investigator’s discretion, patients in the arm could take bicalutamide (Casodex®) for a maximum of 28 days to alleviate increased signs and symptoms due to initial upsurge in testosterone levels.
Leuprolide: Leuprolide treatment for complete study period (one starting dose and 5 maintenance doses of 3-month depot each).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="175">Full Analysis Set Patients</participants>
                <participants group_id="P2" count="50">Full Analysis Set Patients</participants>
                <participants group_id="P3" count="178">Full Analysis Set Patients</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Full Phase B Analysis Set</title>
              <participants_list>
                <participants group_id="P1" count="137">Patients completing 7 months treatment with PSA&lt;2 ng/mL, and having one primary efficacy assessment.</participants>
                <participants group_id="P2" count="41">Patients completing 7 months treatment with PSA&lt;2 ng/mL, and having one primary efficacy assessment.</participants>
                <participants group_id="P3" count="150">Patients completing 7 months treatment with PSA&lt;2 ng/mL, and having one primary efficacy assessment.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="131"/>
                <participants group_id="P2" count="36"/>
                <participants group_id="P3" count="134"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="44"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>PSA failure (&gt;2 ng/mL) at Visit 8</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>PSA failure (&gt;2 ng/mL) on other visit</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other (not meeting above criteria)</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Analysis population consist of Full Analysis Set (FAS), which comprised of subjects who received at least one dose of IMP and had at least one efficacy assessment after dosing.</population>
      <group_list>
        <group group_id="B1">
          <title>DI (Degarelix Intermittent)</title>
          <description>Patients in this arm received degarelix with a starting dose of 240 mg at a concentration of 40 mg/mL on Day 0 administered subcutaneously (s.c.) into the anterior abdominal wall via two equivalent injections of 120 mg (3 mL) each.
Six maintenance doses of degarelix 80 mg per month at a concentration of 20 mg/mL (4 mL) at Days 28 to 168 were administered.
During Phase B of the trial, If a patient had Prostate Specific Antigen (PSA) ≥2 ng/mL at any visit, additional doses of degarelix 240 mg followed by 80 mg maintenance dose(s) were administered.
Degarelix: Degarelix treatment provided for first seven months (one starting dose and six maintenance doses) followed by no treatment for next seven months period.</description>
        </group>
        <group group_id="B2">
          <title>DC (Degarelix Continuous)</title>
          <description>Patients in this arm received degarelix with a starting dose of 240 mg at a concentration of 40 mg/mL administered on Day 0 (Visit 1) s.c. into the anterior abdominal wall via two equivalent injections of 120 mg (3 mL) each.
Thirteen maintenance doses of degarelix 80 mg per month at a concentration of 20 mg/mL (4 mL) at Days 28 to 364, administered s.c. into the anterior abdominal wall
Degarelix: Degarelix treatment provided for complete study period (one starting dose and 13 maintenance doses).</description>
        </group>
        <group group_id="B3">
          <title>LC (Leuprolide Continuous)</title>
          <description>Patients in this arm received leuprolide 7.5 mg one-month depot injection on Day 0, administered intramuscular (i.m.) into a large muscle, as per manufacturer’s labeling directions.
One injection of 22.5 mg leuprolide 3-month depot was administered i.m. as per manufacturer’s labeling directions at Day 28 and every 3 months afterwards for 4 additional doses (i.e at Days 112, 196, 280, and 364, respectively).
On Investigator’s discretion, patients in the arm could take bicalutamide (Casodex®) for a maximum of 28 days to alleviate increased signs and symptoms due to initial upsurge in testosterone levels.
Leuprolide: Leuprolide treatment for complete study period (one starting dose and 5 maintenance doses of 3-month depot each)</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="175"/>
            <count group_id="B2" value="50"/>
            <count group_id="B3" value="178"/>
            <count group_id="B4" value="403"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71.9" spread="8.89"/>
                    <measurement group_id="B2" value="71.7" spread="8.14"/>
                    <measurement group_id="B3" value="71.0" spread="8.44"/>
                    <measurement group_id="B4" value="71.5" spread="8.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="175"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="178"/>
                    <measurement group_id="B4" value="403"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="158"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="164"/>
                    <measurement group_id="B4" value="368"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="140"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="137"/>
                    <measurement group_id="B4" value="316"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>Meter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.77" spread="0.089"/>
                    <measurement group_id="B2" value="1.74" spread="0.089"/>
                    <measurement group_id="B3" value="1.76" spread="0.080"/>
                    <measurement group_id="B4" value="1.76" spread="0.085"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>Kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90.3" spread="19.4"/>
                    <measurement group_id="B2" value="88.4" spread="15.8"/>
                    <measurement group_id="B3" value="91.9" spread="16.9"/>
                    <measurement group_id="B4" value="90.8" spread="17.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>Kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.9" spread="5.45"/>
                    <measurement group_id="B2" value="29.2" spread="4.89"/>
                    <measurement group_id="B3" value="29.6" spread="4.94"/>
                    <measurement group_id="B4" value="29.2" spread="5.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prostate Specific Antigen (PSA)</title>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16.4" spread="66.3"/>
                    <measurement group_id="B2" value="15.6" spread="32.2"/>
                    <measurement group_id="B3" value="10.7" spread="24.4"/>
                    <measurement group_id="B4" value="13.8" spread="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Testosterone</title>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.65" spread="1.43"/>
                    <measurement group_id="B2" value="3.90" spread="1.59"/>
                    <measurement group_id="B3" value="3.76" spread="1.58"/>
                    <measurement group_id="B4" value="3.73" spread="1.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Patients With Serum PSA Levels ≤4.0 ng/mL</title>
        <description>Percentage of patients with serum PSA levels ≤4.0 ng/mL at 14 month was presented.</description>
        <time_frame>At 14 month</time_frame>
        <population>Analysis set consist of Full Phase B Analysis Set, which comprised of patients who completed 7 months of treatment and had a PSA ≤2.0 ng/mL at the end of Month 7 and had at least one primary endpoint efficacy assessment after Month 7.</population>
        <group_list>
          <group group_id="O1">
            <title>DI (Degarelix Intermittent)</title>
            <description>Patients in this arm received degarelix with a starting dose of 240 mg at a concentration of 40 mg/mL on Day 0 (Visit 1) administered subcutaneously (s.c.) into the anterior abdominal wall via two equivalent injections of 120 mg (3 mL) each.
Six maintenance doses of degarelix 80 mg per month at a concentration of 20 mg/mL (4 mL) at Days 28 to 168 (Visit 2 through 7), administered s.c. into the anterior abdominal wall
During Phase B of the trial, If a patient had Prostate Specific Antigen (PSA) ≥2 ng/mL at any visit, additional doses of degarelix 240 mg followed by 80 mg maintenance dose(s) were administered.
Degarelix: Degarelix treatment provided for first seven months (one starting dose and six maintenance doses) followed by no treatment for next seven months period.</description>
          </group>
          <group group_id="O2">
            <title>Total Continuous</title>
            <description>This is the combination of degarelix continuous and leuprolide continuous treatment arms.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With Serum PSA Levels ≤4.0 ng/mL</title>
          <description>Percentage of patients with serum PSA levels ≤4.0 ng/mL at 14 month was presented.</description>
          <population>Analysis set consist of Full Phase B Analysis Set, which comprised of patients who completed 7 months of treatment and had a PSA ≤2.0 ng/mL at the end of Month 7 and had at least one primary endpoint efficacy assessment after Month 7.</population>
          <units>Percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="191"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="97.3" upper_limit="100"/>
                    <measurement group_id="O2" value="98.4" lower_limit="95.5" upper_limit="99.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was defined as a lower bound (LCL) of the 95% confidence interval for the difference between the intermittent and pooled continuous treatments, CADT, (intermittent – continuous) of greater than -12.5%.</non_inferiority_desc>
            <param_type>Percentage difference</param_type>
            <param_value>1.57</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.19</ci_lower_limit>
            <ci_upper_limit>3.33</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in Serum PSA Levels</title>
        <description>Absolute change from Baseline in serum PSA levels during the study period was measured.</description>
        <time_frame>Phase A Visit 1-8 and Phase B Visit 9-15.</time_frame>
        <population>Analysis set consist of Full Phase B Analysis Set, which comprised of patients who completed 7 months of treatment and had a PSA ≤2.0 ng/mL at the end of Month 7 and had at least one primary endpoint efficacy assessment after Month 7.</population>
        <group_list>
          <group group_id="O1">
            <title>DI (Degarelix Intermittent)</title>
            <description>Patients in this arm received degarelix with a starting dose of 240 mg at a concentration of 40 mg/mL on Day 0 (Visit 1) administered subcutaneously (s.c.) into the anterior abdominal wall via two equivalent injections of 120 mg (3 mL) each.
Six maintenance doses of degarelix 80 mg per month at a concentration of 20 mg/mL (4 mL) at Days 28 to 168 (Visit 2 through 7), administered s.c. into the anterior abdominal wall.
During Phase B of the trial, If a patient had Prostate Specific Antigen (PSA) ≥2 ng/mL at any visit, additional doses of degarelix 240 mg followed by 80 mg maintenance dose(s) were administered.
Degarelix: Degarelix treatment provided for first seven months (one starting dose and six maintenance doses) followed by no treatment for next seven months period.</description>
          </group>
          <group group_id="O2">
            <title>DC (Degarelix Continuous)</title>
            <description>Patients in this arm received degarelix with a starting dose of 240 mg at a concentration of 40 mg/mL administered on Day 0 (Visit 1) s.c. into the anterior abdominal wall via two equivalent injections of 120 mg (3 mL) each.
Thirteen maintenance doses of degarelix 80 mg per month at a concentration of 20 mg/mL (4 mL) at Days 28 to 364, administered s.c. into the anterior abdominal wall
Degarelix: Degarelix treatment provided for complete study period (one starting dose and 13 maintenance doses).</description>
          </group>
          <group group_id="O3">
            <title>LC (Leuprolide Continuous)</title>
            <description>Patients in this arm received leuprolide 7.5 mg one-month depot injection on Day 0 (Visit 1), administered intramuscular (i.m.) into a large muscle, as per manufacturer’s labeling directions.
One injection of 22.5 mg leuprolide 3-month depot was administered i.m. into a large muscle, according to the directions for use in the manufacturer’s labeling at Day 28 and every 3 months afterwards for 4 additional doses (i.e at Days 112, 196, 280, and 364, respectively).
On Investigator’s discretion, patients in the arm could take bicalutamide (Casodex®) for a maximum of 28 days to alleviate increased signs and symptoms due to initial upsurge in testosterone levels.
Leuprolide: Leuprolide treatment for complete study period (one starting dose and 5 maintenance doses of 3-month depot each).</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in Serum PSA Levels</title>
          <description>Absolute change from Baseline in serum PSA levels during the study period was measured.</description>
          <population>Analysis set consist of Full Phase B Analysis Set, which comprised of patients who completed 7 months of treatment and had a PSA ≤2.0 ng/mL at the end of Month 7 and had at least one primary endpoint efficacy assessment after Month 7.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Phase A, Visit 1 (Day 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">This visit was the first dosing visit. Serum samples were collected pre-dosing on this visit. Thus, the estimated value obtained on this visit were considered as Baseline value. Hence no change is reported.</measurement>
                    <measurement group_id="O2" value="-0.91">One patient erroneously received medication prior to this visit. Thus, the value obtained on this visit was considered as first post-baseline value for this patient and is reported. There was no SD.</measurement>
                    <measurement group_id="O3" value="NA">This visit was the first dosing visit. Serum samples were collected pre-dosing on this visit. Thus, the estimated value obtained on this visit were considered as Baseline value. Hence no change is reported.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase A, Visit 2 (Month 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.39" spread="10.2"/>
                    <measurement group_id="O2" value="-14.3" spread="34.8"/>
                    <measurement group_id="O3" value="-6.38" spread="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase A, Visit 3 (Month 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.94" spread="10.8"/>
                    <measurement group_id="O2" value="-14.8" spread="34.9"/>
                    <measurement group_id="O3" value="-8.12" spread="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase A, Visit 4 (Month 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.07" spread="10.9"/>
                    <measurement group_id="O2" value="-15" spread="35"/>
                    <measurement group_id="O3" value="-8.44" spread="15.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase A, Visit 5 (Month 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.16" spread="11"/>
                    <measurement group_id="O2" value="-15.1" spread="35.2"/>
                    <measurement group_id="O3" value="-8.51" spread="15.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase A, Visit 6 (Month 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.19" spread="11"/>
                    <measurement group_id="O2" value="-15.1" spread="35.2"/>
                    <measurement group_id="O3" value="-8.59" spread="15.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase A, Visit 7 (Month 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.21" spread="10.9"/>
                    <measurement group_id="O2" value="-15.1" spread="35.2"/>
                    <measurement group_id="O3" value="-8.64" spread="15.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase A, Visit 8 (Month 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.24" spread="11"/>
                    <measurement group_id="O2" value="-15.1" spread="35.2"/>
                    <measurement group_id="O3" value="-8.64" spread="15.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Visit 9 (Month 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.25" spread="11"/>
                    <measurement group_id="O2" value="-15" spread="34.7"/>
                    <measurement group_id="O3" value="-8.64" spread="15.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Visit 10 (Month 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.18" spread="11"/>
                    <measurement group_id="O2" value="-15" spread="34.7"/>
                    <measurement group_id="O3" value="-8.64" spread="15.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Visit 11 (Month 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.07" spread="10.9"/>
                    <measurement group_id="O2" value="-14.9" spread="34.3"/>
                    <measurement group_id="O3" value="-8.63" spread="15.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Visit 12 (Month 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.96" spread="10.9"/>
                    <measurement group_id="O2" value="-14.9" spread="33.9"/>
                    <measurement group_id="O3" value="-8.64" spread="15.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Visit 13 (Month 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.81" spread="11"/>
                    <measurement group_id="O2" value="-14.8" spread="33.9"/>
                    <measurement group_id="O3" value="-8.64" spread="15.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Visit 14 (Month 13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.79" spread="11"/>
                    <measurement group_id="O2" value="-14.8" spread="33.9"/>
                    <measurement group_id="O3" value="-8.59" spread="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Visit 15 (Month 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.74" spread="11"/>
                    <measurement group_id="O2" value="-14.8" spread="33.9"/>
                    <measurement group_id="O3" value="-8.6" spread="15.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Serum PSA Levels</title>
        <description>Percent change from Baseline in serum PSA levels during the study period was measured.</description>
        <time_frame>Phase A Visit 1-8 and Phase B Visit 9-15.</time_frame>
        <population>Analysis set consist of Full Phase B analysis set, which comprised of patients who completed 7 months of treatment and had a PSA ≤2.0 ng/mL at the end of Month 7 and had at least one primary endpoint efficacy assessment after Month 7.</population>
        <group_list>
          <group group_id="O1">
            <title>DI (Degarelix Intermittent)</title>
            <description>Patients in this arm received degarelix with a starting dose of 240 mg at a concentration of 40 mg/mL on Day 0 (Visit 1) administered subcutaneously (s.c.) into the anterior abdominal wall via two equivalent injections of 120 mg (3 mL) each.
Six maintenance doses of degarelix 80 mg per month at a concentration of 20 mg/mL (4 mL) at Days 28 to 168 (Visit 2 through 7), administered s.c. into the anterior abdominal wall.
During Phase B of the trial, If a patient had Prostate Specific Antigen (PSA) ≥2 ng/mL at any visit, additional doses of degarelix 240 mg followed by 80 mg maintenance dose(s) were administered.
Degarelix: Degarelix treatment provided for first seven months (one starting dose and six maintenance doses) followed by no treatment for next seven months period.</description>
          </group>
          <group group_id="O2">
            <title>DC (Degarelix Continuous)</title>
            <description>Patients in this arm received degarelix with a starting dose of 240 mg at a concentration of 40 mg/mL administered on Day 0 (Visit 1) s.c. into the anterior abdominal wall via two equivalent injections of 120 mg (3 mL) each.
Thirteen maintenance doses of degarelix 80 mg per month at a concentration of 20 mg/mL (4 mL) at Days 28 to 364, administered s.c. into the anterior abdominal wall
Degarelix: Degarelix treatment provided for complete study period (one starting dose and 13 maintenance doses).</description>
          </group>
          <group group_id="O3">
            <title>LC (Leuprolide Continuous)</title>
            <description>Patients in this arm received leuprolide 7.5 mg one-month depot injection on Day 0 (Visit 1), administered intramuscular (i.m.) into a large muscle, as per manufacturer’s labeling directions.
One injection of 22.5 mg leuprolide 3-month depot was administered i.m. into a large muscle, according to the directions for use in the manufacturer’s labeling at Day 28 and every 3 months afterwards for 4 additional doses (i.e at Days 112, 196, 280, and 364, respectively).
On Investigator’s discretion, patients in the arm could take bicalutamide (Casodex®) for a maximum of 28 days to alleviate increased signs and symptoms due to initial upsurge in testosterone levels.
Leuprolide: Leuprolide treatment for complete study period (one starting dose and 5 maintenance doses of 3-month depot each).</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Serum PSA Levels</title>
          <description>Percent change from Baseline in serum PSA levels during the study period was measured.</description>
          <population>Analysis set consist of Full Phase B analysis set, which comprised of patients who completed 7 months of treatment and had a PSA ≤2.0 ng/mL at the end of Month 7 and had at least one primary endpoint efficacy assessment after Month 7.</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Phase A, Visit 1 (Day 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">This visit was the first dosing visit. Serum samples were collected pre-dosing on this visit. Thus, the estimated value obtained on this visit were considered as Baseline value. Hence no change is reported.</measurement>
                    <measurement group_id="O2" value="-39.6">One patient erroneously received medication prior to this visit. Thus, the value obtained on this visit was considered as first post-baseline value for this patient and is reported. There was no SD.</measurement>
                    <measurement group_id="O3" value="NA">This visit was the first dosing visit. Serum samples were collected pre-dosing on this visit. Thus, the estimated value obtained on this visit were considered as Baseline value. Hence no change is reported.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase A, Visit 2 (Month 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-80.8" spread="24.4"/>
                    <measurement group_id="O2" value="-84.5" spread="11.8"/>
                    <measurement group_id="O3" value="-62.8" spread="31.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase A, Visit 3 (Month 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-90.4" spread="12.2"/>
                    <measurement group_id="O2" value="-92.4" spread="8.23"/>
                    <measurement group_id="O3" value="-87.3" spread="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase A, Visit 4 (Month 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-92.8" spread="9.9"/>
                    <measurement group_id="O2" value="-94.5" spread="7.37"/>
                    <measurement group_id="O3" value="-92.3" spread="7.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase A, Visit 5 (Month 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-94.1" spread="8.45"/>
                    <measurement group_id="O2" value="-95.5" spread="7.05"/>
                    <measurement group_id="O3" value="-93.4" spread="9.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase A, Visit 6 (Month 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-94.2" spread="9.31"/>
                    <measurement group_id="O2" value="-95.7" spread="7.8"/>
                    <measurement group_id="O3" value="-94.5" spread="7.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase A, Visit 7 (Month 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-94.8" spread="8.34"/>
                    <measurement group_id="O2" value="-95.8" spread="8.64"/>
                    <measurement group_id="O3" value="-95.3" spread="7.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase A, Visit 8 (Month 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-95.4" spread="7.13"/>
                    <measurement group_id="O2" value="-95.4" spread="10.8"/>
                    <measurement group_id="O3" value="-95.5" spread="7.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Visit 9 (Month 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-95.7" spread="6.97"/>
                    <measurement group_id="O2" value="-95.5" spread="10.3"/>
                    <measurement group_id="O3" value="-95.2" spread="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Visit 10 (Month 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-93.6" spread="11.5"/>
                    <measurement group_id="O2" value="-95.6" spread="10.6"/>
                    <measurement group_id="O3" value="-94.3" spread="23.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Visit 11 (Month 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-91.9" spread="13.4"/>
                    <measurement group_id="O2" value="-95.7" spread="9.46"/>
                    <measurement group_id="O3" value="-93.1" spread="24.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Visit 12 (Month 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-88" spread="22.7"/>
                    <measurement group_id="O2" value="-95.1" spread="11.9"/>
                    <measurement group_id="O3" value="-94.4" spread="23.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Visit 13 (Month 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-84.2" spread="24.9"/>
                    <measurement group_id="O2" value="-95.1" spread="10.6"/>
                    <measurement group_id="O3" value="-94.5" spread="23.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Visit 14 (Month 13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-82.8" spread="24.9"/>
                    <measurement group_id="O2" value="-95.1" spread="10.4"/>
                    <measurement group_id="O3" value="-93.1" spread="25.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Visit 15 (Month 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-80.8" spread="26.4"/>
                    <measurement group_id="O2" value="-94.4" spread="12.9"/>
                    <measurement group_id="O3" value="-93.7" spread="25.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Quality of Life as Assessed by the Functional Assessment of Cancer Therapy–Prostate (FACT-P) : Physical Well-being</title>
        <description>The FACT-P is a multidimensional, self-report quality of life (QoL) instrument specifically designed for use with prostate cancer patients. It consists of 27 core items which assess patient function in four domains: Physical, Social/Family, Emotional, and Functional well-being, which is further supplemented by 12 site specific items to assess for prostate related symptoms. Each question is rated on a scale from 0 to 4, and then combined to produce sub-scale scores for each domain, as well as a global QoL score.
Physical well-being consist of 7 items and scored on a scale of 0-4 (0=Not at all; 1=A little bit; 2=Somewhat; 3=Quite a bit; 4=Very much). Total score for the physical well-being sub scale ranges from 0 to 28. Higher scores represent better QoL.</description>
        <time_frame>During 14 months</time_frame>
        <population>Analysis set consist of Full Phase B Analysis Set, which comprised of patients who completed 7 months of treatment and had a PSA ≤2.0 ng/mL at the end of Month 7 and had at least one primary endpoint efficacy assessment after Month 7.</population>
        <group_list>
          <group group_id="O1">
            <title>DI (Degarelix Intermittent)</title>
            <description>Patients in this arm received degarelix with a starting dose of 240 mg at a concentration of 40 mg/mL on Day 0 (Visit 1) administered subcutaneously (s.c.) into the anterior abdominal wall via two equivalent injections of 120 mg (3 mL) each.
Six maintenance doses of degarelix 80 mg per month at a concentration of 20 mg/mL (4 mL) at Days 28 to 168 (Visit 2 through 7), administered s.c. into the anterior abdominal wall.
During Phase B of the trial, If a patient had Prostate Specific Antigen (PSA) ≥2 ng/mL at any visit, additional doses of degarelix 240 mg followed by 80 mg maintenance dose(s) were administered.
Degarelix: Degarelix treatment provided for first seven months (one starting dose and six maintenance doses) followed by no treatment for next seven months period.</description>
          </group>
          <group group_id="O2">
            <title>DC (Degarelix Continuous)</title>
            <description>Patients in this arm received degarelix with a starting dose of 240 mg at a concentration of 40 mg/mL administered on Day 0 (Visit 1) s.c. into the anterior abdominal wall via two equivalent injections of 120 mg (3 mL) each. Thirteen maintenance doses of degarelix 80 mg per month at a concentration of 20 mg/mL (4 mL) at Days 28 to 364, administered s.c. into the anterior abdominal wall
Degarelix: Degarelix treatment provided for complete study period (one starting dose and 13 maintenance doses).</description>
          </group>
          <group group_id="O3">
            <title>LC (Leuprolide Continuous)</title>
            <description>Patients in this arm received leuprolide 7.5 mg one-month depot injection on Day 0 (Visit 1), administered intramuscular (i.m.) into a large muscle, as per manufacturer’s labeling directions.
One injection of 22.5 mg leuprolide 3-month depot was administered i.m. into a large muscle, according to the directions for use in the manufacturer’s labeling at Day 28 and every 3 months afterwards for 4 additional doses (i.e at Days 112, 196, 280, and 364, respectively).
On Investigator’s discretion, patients in the arm could take bicalutamide (Casodex®) for a maximum of 28 days to alleviate increased signs and symptoms due to initial upsurge in testosterone levels.
Leuprolide: Leuprolide treatment for complete study period (one starting dose and 5 maintenance doses of 3- month depot each).</description>
          </group>
          <group group_id="O4">
            <title>Total Continuous</title>
            <description>This is the combination of degarelix continuous and leuprolide continuous treatment arms.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Quality of Life as Assessed by the Functional Assessment of Cancer Therapy–Prostate (FACT-P) : Physical Well-being</title>
          <description>The FACT-P is a multidimensional, self-report quality of life (QoL) instrument specifically designed for use with prostate cancer patients. It consists of 27 core items which assess patient function in four domains: Physical, Social/Family, Emotional, and Functional well-being, which is further supplemented by 12 site specific items to assess for prostate related symptoms. Each question is rated on a scale from 0 to 4, and then combined to produce sub-scale scores for each domain, as well as a global QoL score.
Physical well-being consist of 7 items and scored on a scale of 0-4 (0=Not at all; 1=A little bit; 2=Somewhat; 3=Quite a bit; 4=Very much). Total score for the physical well-being sub scale ranges from 0 to 28. Higher scores represent better QoL.</description>
          <population>Analysis set consist of Full Phase B Analysis Set, which comprised of patients who completed 7 months of treatment and had a PSA ≤2.0 ng/mL at the end of Month 7 and had at least one primary endpoint efficacy assessment after Month 7.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="150"/>
                <count group_id="O4" value="191"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Phase A, Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.47" lower_limit="-1.99" upper_limit="-0.94"/>
                    <measurement group_id="O2" value="-1.63" lower_limit="-2.59" upper_limit="-0.67"/>
                    <measurement group_id="O3" value="-1.41" lower_limit="-1.92" upper_limit="-0.90"/>
                    <measurement group_id="O4" value="-1.46" lower_limit="-1.90" upper_limit="-1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase A, Month 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.41" lower_limit="-1.93" upper_limit="-0.88"/>
                    <measurement group_id="O2" value="-1.48" lower_limit="-2.43" upper_limit="-0.52"/>
                    <measurement group_id="O3" value="-1.67" lower_limit="-2.17" upper_limit="-1.17"/>
                    <measurement group_id="O4" value="-1.63" lower_limit="-2.07" upper_limit="-1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Month 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.96" lower_limit="-1.46" upper_limit="-0.46"/>
                    <measurement group_id="O2" value="-1.92" lower_limit="-2.83" upper_limit="-1.01"/>
                    <measurement group_id="O3" value="-1.74" lower_limit="-2.22" upper_limit="-1.27"/>
                    <measurement group_id="O4" value="-1.78" lower_limit="-2.20" upper_limit="-1.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.24" lower_limit="-1.80" upper_limit="-0.68"/>
                    <measurement group_id="O2" value="-1.85" lower_limit="-2.87" upper_limit="-0.82"/>
                    <measurement group_id="O3" value="-1.77" lower_limit="-2.31" upper_limit="-1.24"/>
                    <measurement group_id="O4" value="-1.79" lower_limit="-2.26" upper_limit="-1.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Month 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.05" lower_limit="-1.63" upper_limit="-0.48"/>
                    <measurement group_id="O2" value="-2.08" lower_limit="-3.13" upper_limit="-1.03"/>
                    <measurement group_id="O3" value="-1.68" lower_limit="-2.23" upper_limit="-1.13"/>
                    <measurement group_id="O4" value="-1.76" lower_limit="-2.25" upper_limit="-1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Month 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.00" lower_limit="-1.56" upper_limit="-0.44"/>
                    <measurement group_id="O2" value="-1.77" lower_limit="-2.79" upper_limit="-0.75"/>
                    <measurement group_id="O3" value="-1.53" lower_limit="-2.07" upper_limit="-1.00"/>
                    <measurement group_id="O4" value="-1.58" lower_limit="-2.05" upper_limit="-1.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.91" lower_limit="-1.44" upper_limit="-0.38"/>
                    <measurement group_id="O2" value="-1.62" lower_limit="-2.59" upper_limit="-0.66"/>
                    <measurement group_id="O3" value="-1.32" lower_limit="-1.83" upper_limit="-0.82"/>
                    <measurement group_id="O4" value="-1.39" lower_limit="-1.83" upper_limit="-0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Month 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.00" lower_limit="-1.57" upper_limit="-0.43"/>
                    <measurement group_id="O2" value="-2.10" lower_limit="-3.14" upper_limit="-1.06"/>
                    <measurement group_id="O3" value="-1.40" lower_limit="-1.95" upper_limit="-0.86"/>
                    <measurement group_id="O4" value="-1.55" lower_limit="-2.04" upper_limit="-1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Month 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.04" lower_limit="-1.62" upper_limit="-0.47"/>
                    <measurement group_id="O2" value="-1.90" lower_limit="-2.95" upper_limit="-0.85"/>
                    <measurement group_id="O3" value="-1.45" lower_limit="-2.00" upper_limit="-0.91"/>
                    <measurement group_id="O4" value="-1.55" lower_limit="-2.03" upper_limit="-1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Quality of Life as Assessed by the FACT-P : Emotional Well-being</title>
        <description>The FACT-P is a multidimensional, self-report quality of life (QoL) instrument specifically designed for use with prostate cancer patients. It consists of 27 core items which assess patient function in four domains: Physical, Social/Family, Emotional, and Functional well-being, which is further supplemented by 12 site specific items to assess for prostate related symptoms. Each question is rated on a scale from 0 to 4, and then combined to produce sub-scale scores for each domain, as well as a global QoL score.
Emotional well-being consist of 6 items and scored on a scale of 0-4 (0=Not at all; 1=A little bit; 2=Somewhat; 3=Quite a bit; 4=Very much). Total score for the emotional well-being sub scale ranges from 0 to 24. Higher scores represent better QoL.Higher scores represent better QoL.</description>
        <time_frame>During 14 months</time_frame>
        <population>Analysis set consist of Full Phase B Analysis Set, which comprised of patients who completed 7 months of treatment and had a PSA ≤2.0 ng/mL at the end of Month 7 and had at least one primary endpoint efficacy assessment after Month 7.</population>
        <group_list>
          <group group_id="O1">
            <title>DI (Degarelix Intermittent)</title>
            <description>Patients in this arm received degarelix with a starting dose of 240 mg at a concentration of 40 mg/mL on Day 0 (Visit 1) administered subcutaneously (s.c.) into the anterior abdominal wall via two equivalent injections of 120 mg (3 mL) each.
Six maintenance doses of degarelix 80 mg per month at a concentration of 20 mg/mL (4 mL) at Days 28 to 168 (Visit 2 through 7), administered s.c. into the anterior abdominal wall.
During Phase B of the trial, If a patient had Prostate Specific Antigen (PSA) ≥2 ng/mL at any visit, additional doses of degarelix 240 mg followed by 80 mg maintenance dose(s) were administered.
Degarelix: Degarelix treatment provided for first seven months (one starting dose and six maintenance doses) followed by no treatment for next seven months period.</description>
          </group>
          <group group_id="O2">
            <title>DC (Degarelix Continuous)</title>
            <description>administered on Day 0 (Visit 1) s.c. into the anterior abdominal wall via two equivalent injections of 120 mg (3 mL) each.
Thirteen maintenance doses of degarelix 80 mg per month at a concentration of 20 mg/mL (4 mL) at Days 28 to 364, administered s.c. into the anterior abdominal wall.
Degarelix: Degarelix treatment provided for complete study period (one starting dose and 13 maintenance doses).</description>
          </group>
          <group group_id="O3">
            <title>LC (Leuprolide Continuous)</title>
            <description>Patients in this arm received leuprolide 7.5 mg one-month depot injection on Day 0 (Visit 1), administered intramuscular (i.m.) into a large muscle, as per manufacturer’s labeling directions.
One injection of 22.5 mg leuprolide 3-month depot was administered i.m. into a large muscle, according to the directions for use in the manufacturer’s labeling at Day 28 and every 3 months afterwards for 4 additional doses (i.e at Days 112, 196, 280, and 364, respectively).
On Investigator’s discretion, patients in the arm could take bicalutamide (Casodex®) for a maximum of 28 days to alleviate increased signs and symptoms due to initial upsurge in testosterone levels.
Leuprolide: Leuprolide treatment for complete study period (one starting dose and 5 maintenance doses of 3- month depot each).</description>
          </group>
          <group group_id="O4">
            <title>Total Continuous</title>
            <description>This is the combination of degarelix continuous and leuprolide continuous treatment arms.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Quality of Life as Assessed by the FACT-P : Emotional Well-being</title>
          <description>The FACT-P is a multidimensional, self-report quality of life (QoL) instrument specifically designed for use with prostate cancer patients. It consists of 27 core items which assess patient function in four domains: Physical, Social/Family, Emotional, and Functional well-being, which is further supplemented by 12 site specific items to assess for prostate related symptoms. Each question is rated on a scale from 0 to 4, and then combined to produce sub-scale scores for each domain, as well as a global QoL score.
Emotional well-being consist of 6 items and scored on a scale of 0-4 (0=Not at all; 1=A little bit; 2=Somewhat; 3=Quite a bit; 4=Very much). Total score for the emotional well-being sub scale ranges from 0 to 24. Higher scores represent better QoL.Higher scores represent better QoL.</description>
          <population>Analysis set consist of Full Phase B Analysis Set, which comprised of patients who completed 7 months of treatment and had a PSA ≤2.0 ng/mL at the end of Month 7 and had at least one primary endpoint efficacy assessment after Month 7.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="150"/>
                <count group_id="O4" value="191"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Phase A, Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.69" lower_limit="0.18" upper_limit="1.20"/>
                    <measurement group_id="O2" value="1.31" lower_limit="0.37" upper_limit="2.24"/>
                    <measurement group_id="O3" value="0.76" lower_limit="0.27" upper_limit="1.24"/>
                    <measurement group_id="O4" value="0.88" lower_limit="0.45" upper_limit="1.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase A, Month 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.67" lower_limit="0.16" upper_limit="1.18"/>
                    <measurement group_id="O2" value="0.57" lower_limit="-0.37" upper_limit="1.51"/>
                    <measurement group_id="O3" value="0.90" lower_limit="0.42" upper_limit="1.39"/>
                    <measurement group_id="O4" value="0.83" lower_limit="0.40" upper_limit="1.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Month 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.65" lower_limit="0.16" upper_limit="1.14"/>
                    <measurement group_id="O2" value="0.95" lower_limit="0.05" upper_limit="1.86"/>
                    <measurement group_id="O3" value="1.11" lower_limit="0.65" upper_limit="1.58"/>
                    <measurement group_id="O4" value="1.08" lower_limit="0.67" upper_limit="1.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.75" lower_limit="0.27" upper_limit="1.24"/>
                    <measurement group_id="O2" value="1.11" lower_limit="0.22" upper_limit="2.01"/>
                    <measurement group_id="O3" value="1.16" lower_limit="0.70" upper_limit="1.62"/>
                    <measurement group_id="O4" value="1.15" lower_limit="0.74" upper_limit="1.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Month 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.09" lower_limit="0.57" upper_limit="1.60"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-0.94" upper_limit="0.95"/>
                    <measurement group_id="O3" value="0.98" lower_limit="0.49" upper_limit="1.46"/>
                    <measurement group_id="O4" value="0.77" lower_limit="0.34" upper_limit="1.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Month 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.82" lower_limit="0.34" upper_limit="1.30"/>
                    <measurement group_id="O2" value="0.94" lower_limit="0.06" upper_limit="1.83"/>
                    <measurement group_id="O3" value="1.05" lower_limit="0.59" upper_limit="1.50"/>
                    <measurement group_id="O4" value="1.03" lower_limit="0.62" upper_limit="1.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.99" lower_limit="0.47" upper_limit="1.50"/>
                    <measurement group_id="O2" value="1.07" lower_limit="0.12" upper_limit="2.02"/>
                    <measurement group_id="O3" value="1.23" lower_limit="0.74" upper_limit="1.72"/>
                    <measurement group_id="O4" value="1.20" lower_limit="0.76" upper_limit="1.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Month 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.74" lower_limit="0.22" upper_limit="1.26"/>
                    <measurement group_id="O2" value="0.52" lower_limit="-0.43" upper_limit="1.48"/>
                    <measurement group_id="O3" value="1.14" lower_limit="0.64" upper_limit="1.63"/>
                    <measurement group_id="O4" value="1.01" lower_limit="0.57" upper_limit="1.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Month 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.40" lower_limit="-0.13" upper_limit="0.93"/>
                    <measurement group_id="O2" value="0.86" lower_limit="-0.11" upper_limit="1.83"/>
                    <measurement group_id="O3" value="1.12" lower_limit="0.62" upper_limit="1.62"/>
                    <measurement group_id="O4" value="1.06" lower_limit="0.62" upper_limit="1.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Quality of Life as Assessed by the FACT-P : Social Well-being</title>
        <description>The FACT-P is a multidimensional, self-report quality of life (QoL) instrument specifically designed for use with prostate cancer patients. It consists of 27 core items which assess patient function in four domains: Physical, Social/Family, Emotional, and Functional well-being, which is further supplemented by 12 site specific items to assess for prostate related symptoms. Each question is rated on a scale from 0 to 4, and then combined to produce sub-scale scores for each domain, as well as a global QoL score.
Social well-being consist of 7 items and scored on a scale of 0-4 (0=Not at all; 1=A little bit; 2=Somewhat; 3=Quite a bit; 4=Very much). Total score for the social well-being sub scale ranges from 0 to 28. Higher scores represent better QoL.</description>
        <time_frame>During 14 months</time_frame>
        <population>Analysis set consist of Full Phase B Analysis Set, which comprised of patients who completed 7 months of treatment and had a PSA ≤2.0 ng/mL at the end of Month 7 and had at least one primary endpoint efficacy assessment after Month 7.</population>
        <group_list>
          <group group_id="O1">
            <title>DI (Degarelix Intermittent)</title>
            <description>Patients in this arm received degarelix with a starting dose of 240 mg at a concentration of 40 mg/mL on Day 0 (Visit 1) administered subcutaneously (s.c.) into the anterior abdominal wall via two equivalent injections of 120 mg (3 mL) each.
Six maintenance doses of degarelix 80 mg per month at a concentration of 20 mg/mL (4 mL) at Days 28 to 168 (Visit 2 through 7), administered s.c. into the anterior abdominal wall.
During Phase B of the trial, If a patient had Prostate Specific Antigen (PSA) ≥2 ng/mL at any visit, additional doses of degarelix 240 mg followed by 80 mg maintenance dose(s) were administered.
Degarelix: Degarelix treatment provided for first seven months (one starting dose and six maintenance doses) followed by no treatment for next seven months period.</description>
          </group>
          <group group_id="O2">
            <title>DC (Degarelix Continuous)</title>
            <description>Patients in this arm received degarelix with a starting dose of 240 mg at a concentration of 40 mg/mL administered on Day 0 (Visit 1) s.c. into the anterior abdominal wall via two equivalent injections of 120 mg (3 mL) each.
Thirteen maintenance doses of degarelix 80 mg per month at a concentration of 20 mg/mL (4 mL) at Days 28 to 364, administered s.c. into the anterior abdominal wall.
Degarelix: Degarelix treatment provided for complete study period (one starting dose and 13 maintenance doses).</description>
          </group>
          <group group_id="O3">
            <title>LC (Leuprolide Continuous)</title>
            <description>Patients in this arm received leuprolide 7.5 mg one-month depot injection on Day 0 (Visit 1), administered intramuscular (i.m.) into a large muscle, as per manufacturer’s labeling directions.
One injection of 22.5 mg leuprolide 3-month depot was administered i.m. into a large muscle, according to the directions for use in the manufacturer’s labeling at Day 28 and every 3 months afterwards for 4 additional doses (i.e at Days 112, 196, 280, and 364, respectively).
On Investigator’s discretion, patients in the arm could take bicalutamide (Casodex®) for a maximum of 28 days to alleviate increased signs and symptoms due to initial upsurge in testosterone levels.
Leuprolide: Leuprolide treatment for complete study period (one starting dose and 5 maintenance doses of 3- month depot each).</description>
          </group>
          <group group_id="O4">
            <title>Total Continuous</title>
            <description>This is the combination of degarelix continuous and leuprolide continuous treatment arms.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Quality of Life as Assessed by the FACT-P : Social Well-being</title>
          <description>The FACT-P is a multidimensional, self-report quality of life (QoL) instrument specifically designed for use with prostate cancer patients. It consists of 27 core items which assess patient function in four domains: Physical, Social/Family, Emotional, and Functional well-being, which is further supplemented by 12 site specific items to assess for prostate related symptoms. Each question is rated on a scale from 0 to 4, and then combined to produce sub-scale scores for each domain, as well as a global QoL score.
Social well-being consist of 7 items and scored on a scale of 0-4 (0=Not at all; 1=A little bit; 2=Somewhat; 3=Quite a bit; 4=Very much). Total score for the social well-being sub scale ranges from 0 to 28. Higher scores represent better QoL.</description>
          <population>Analysis set consist of Full Phase B Analysis Set, which comprised of patients who completed 7 months of treatment and had a PSA ≤2.0 ng/mL at the end of Month 7 and had at least one primary endpoint efficacy assessment after Month 7.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="150"/>
                <count group_id="O4" value="191"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Phase A, Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.18" lower_limit="-0.96" upper_limit="0.60"/>
                    <measurement group_id="O2" value="-0.06" lower_limit="-1.48" upper_limit="1.35"/>
                    <measurement group_id="O3" value="-0.36" lower_limit="-1.11" upper_limit="0.38"/>
                    <measurement group_id="O4" value="-0.30" lower_limit="-0.95" upper_limit="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase A, Month 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-0.79" upper_limit="0.79"/>
                    <measurement group_id="O2" value="-0.30" lower_limit="-1.75" upper_limit="1.14"/>
                    <measurement group_id="O3" value="-0.46" lower_limit="-1.21" upper_limit="0.29"/>
                    <measurement group_id="O4" value="-0.43" lower_limit="-1.09" upper_limit="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Month 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.33" lower_limit="-1.06" upper_limit="0.39"/>
                    <measurement group_id="O2" value="-0.52" lower_limit="-1.84" upper_limit="0.80"/>
                    <measurement group_id="O3" value="-0.41" lower_limit="-1.10" upper_limit="0.28"/>
                    <measurement group_id="O4" value="-0.43" lower_limit="-1.04" upper_limit="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" lower_limit="-0.80" upper_limit="0.77"/>
                    <measurement group_id="O2" value="-0.95" lower_limit="-2.37" upper_limit="0.47"/>
                    <measurement group_id="O3" value="-1.10" lower_limit="-1.84" upper_limit="-0.36"/>
                    <measurement group_id="O4" value="-1.07" lower_limit="-1.72" upper_limit="-0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Month 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.36" lower_limit="-0.42" upper_limit="1.14"/>
                    <measurement group_id="O2" value="-1.00" lower_limit="-2.42" upper_limit="0.42"/>
                    <measurement group_id="O3" value="-1.15" lower_limit="-1.89" upper_limit="-0.41"/>
                    <measurement group_id="O4" value="-1.12" lower_limit="-1.77" upper_limit="-0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Month 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" lower_limit="-0.63" upper_limit="1.02"/>
                    <measurement group_id="O2" value="-1.09" lower_limit="-2.59" upper_limit="0.42"/>
                    <measurement group_id="O3" value="-0.83" lower_limit="-1.61" upper_limit="-0.05"/>
                    <measurement group_id="O4" value="-0.88" lower_limit="-1.58" upper_limit="-0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.16" lower_limit="-0.94" upper_limit="0.63"/>
                    <measurement group_id="O2" value="-1.34" lower_limit="-2.78" upper_limit="0.09"/>
                    <measurement group_id="O3" value="-0.85" lower_limit="-1.59" upper_limit="-0.10"/>
                    <measurement group_id="O4" value="-0.95" lower_limit="-1.61" upper_limit="-0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Month 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" lower_limit="-0.79" upper_limit="0.74"/>
                    <measurement group_id="O2" value="-1.35" lower_limit="-2.74" upper_limit="0.03"/>
                    <measurement group_id="O3" value="-0.72" lower_limit="-1.44" upper_limit="0.00"/>
                    <measurement group_id="O4" value="-0.85" lower_limit="-1.49" upper_limit="-0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Month 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.28" lower_limit="-0.44" upper_limit="1.01"/>
                    <measurement group_id="O2" value="-0.68" lower_limit="-2.00" upper_limit="0.64"/>
                    <measurement group_id="O3" value="-0.55" lower_limit="-1.24" upper_limit="0.14"/>
                    <measurement group_id="O4" value="-0.58" lower_limit="-1.19" upper_limit="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Quality of Life as Assessed by the FACT-P : Functional Well-being</title>
        <description>The FACT-P is a multidimensional, self-report quality of life (QoL) instrument specifically designed for use with prostate cancer patients. It consists of 27 core items which assess patient function in four domains: Physical, Social/Family, Emotional, and Functional well-being, which is further supplemented by 12 site specific items to assess for prostate related symptoms. Each question is rated on a scale from 0 to 4, and then combined to produce sub-scale scores for each domain, as well as a global QoL score.
Functional well-being consist of 7 items and scored on a scale of 0-4 (0=Not at all; 1=A little bit; 2=Somewhat; 3=Quite a bit; 4=Very much). Total score for the functional well-being sub scale ranges from 0 to 28. Higher scores represent better QoL.</description>
        <time_frame>During 14 months</time_frame>
        <population>Analysis set consist of Full Phase B Analysis Set, which comprised of patients who completed 7 months of treatment and had a PSA ≤2.0 ng/mL at the end of Month 7 and had at least one primary endpoint efficacy assessment after Month 7.</population>
        <group_list>
          <group group_id="O1">
            <title>DI (Degarelix Intermittent)</title>
            <description>Patients in this arm received degarelix with a starting dose of 240 mg at a concentration of 40 mg/mL on Day 0 (Visit 1) administered subcutaneously (s.c.) into the anterior abdominal wall via two equivalent injections of 120 mg (3 mL) each.
Six maintenance doses of degarelix 80 mg per month at a concentration of 20 mg/mL (4 mL) at Days 28 to 168 (Visit 2 through 7), administered s.c. into the anterior abdominal wall.
During Phase B of the trial, If a patient had Prostate Specific Antigen (PSA) ≥2 ng/mL at any visit, additional doses of degarelix 240 mg followed by 80 mg maintenance dose(s) were administered.
Degarelix: Degarelix treatment provided for first seven months (one starting dose and six maintenance doses) followed by no treatment for next seven months period.</description>
          </group>
          <group group_id="O2">
            <title>DC (Degarelix Continuous)</title>
            <description>Patients in this arm received degarelix with a starting dose of 240 mg at a concentration of 40 mg/mL administered on Day 0 (Visit 1) s.c. into the anterior abdominal wall via two equivalent injections of 120 mg (3 mL) each.
Thirteen maintenance doses of degarelix 80 mg per month at a concentration of 20 mg/mL (4 mL) at Days 28 to 364, administered s.c. into the anterior abdominal wall.
Degarelix: Degarelix treatment provided for complete study period (one starting dose and 13 maintenance doses).</description>
          </group>
          <group group_id="O3">
            <title>LC (Leuprolide Continuous)</title>
            <description>Patients in this arm received leuprolide 7.5 mg one-month depot injection on Day 0 (Visit 1), administered intramuscular (i.m.) into a large muscle, as per manufacturer’s labeling directions.
One injection of 22.5 mg leuprolide 3-month depot was administered i.m. into a large muscle, according to the directions for use in the manufacturer’s labeling at Day 28 and every 3 months afterwards for 4 additional doses (i.e at Days 112, 196, 280, and 364, respectively).
On Investigator’s discretion, patients in the arm could take bicalutamide (Casodex®) for a maximum of 28 days to alleviate increased signs and symptoms due to initial upsurge in testosterone levels.
Leuprolide: Leuprolide treatment for complete study period (one starting dose and 5 maintenance doses of 3-month depot each).</description>
          </group>
          <group group_id="O4">
            <title>Total Continuous</title>
            <description>This is the combination of degarelix continuous and leuprolide continuous treatment arms.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Quality of Life as Assessed by the FACT-P : Functional Well-being</title>
          <description>The FACT-P is a multidimensional, self-report quality of life (QoL) instrument specifically designed for use with prostate cancer patients. It consists of 27 core items which assess patient function in four domains: Physical, Social/Family, Emotional, and Functional well-being, which is further supplemented by 12 site specific items to assess for prostate related symptoms. Each question is rated on a scale from 0 to 4, and then combined to produce sub-scale scores for each domain, as well as a global QoL score.
Functional well-being consist of 7 items and scored on a scale of 0-4 (0=Not at all; 1=A little bit; 2=Somewhat; 3=Quite a bit; 4=Very much). Total score for the functional well-being sub scale ranges from 0 to 28. Higher scores represent better QoL.</description>
          <population>Analysis set consist of Full Phase B Analysis Set, which comprised of patients who completed 7 months of treatment and had a PSA ≤2.0 ng/mL at the end of Month 7 and had at least one primary endpoint efficacy assessment after Month 7.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="150"/>
                <count group_id="O4" value="191"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Phase A, Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.96" lower_limit="-1.70" upper_limit="-0.23"/>
                    <measurement group_id="O2" value="-0.88" lower_limit="-2.23" upper_limit="0.47"/>
                    <measurement group_id="O3" value="-0.29" lower_limit="-0.99" upper_limit="0.41"/>
                    <measurement group_id="O4" value="-0.42" lower_limit="-1.04" upper_limit="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase A, Month 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.41" lower_limit="-2.25" upper_limit="-0.58"/>
                    <measurement group_id="O2" value="-0.78" lower_limit="-2.31" upper_limit="0.76"/>
                    <measurement group_id="O3" value="-1.24" lower_limit="-2.03" upper_limit="-0.45"/>
                    <measurement group_id="O4" value="-1.15" lower_limit="-1.85" upper_limit="-0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Month 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.18" lower_limit="-1.90" upper_limit="-0.45"/>
                    <measurement group_id="O2" value="-1.08" lower_limit="-2.41" upper_limit="0.26"/>
                    <measurement group_id="O3" value="-0.73" lower_limit="-1.42" upper_limit="-0.04"/>
                    <measurement group_id="O4" value="-0.80" lower_limit="-1.41" upper_limit="-0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.14" lower_limit="-1.94" upper_limit="-0.34"/>
                    <measurement group_id="O2" value="-1.07" lower_limit="-2.53" upper_limit="0.40"/>
                    <measurement group_id="O3" value="-1.23" lower_limit="-1.99" upper_limit="-0.47"/>
                    <measurement group_id="O4" value="-1.20" lower_limit="-1.87" upper_limit="-0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Month 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.35" lower_limit="-2.15" upper_limit="-0.54"/>
                    <measurement group_id="O2" value="-0.89" lower_limit="-2.36" upper_limit="0.58"/>
                    <measurement group_id="O3" value="-1.42" lower_limit="-2.18" upper_limit="-0.66"/>
                    <measurement group_id="O4" value="-1.31" lower_limit="-1.98" upper_limit="-0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Month 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.25" lower_limit="-2.08" upper_limit="-0.43"/>
                    <measurement group_id="O2" value="-0.80" lower_limit="-2.32" upper_limit="0.72"/>
                    <measurement group_id="O3" value="-1.24" lower_limit="-2.02" upper_limit="-0.46"/>
                    <measurement group_id="O4" value="-1.15" lower_limit="-1.84" upper_limit="-0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.92" lower_limit="-1.70" upper_limit="-0.15"/>
                    <measurement group_id="O2" value="-1.49" lower_limit="-2.91" upper_limit="-0.07"/>
                    <measurement group_id="O3" value="-0.73" lower_limit="-1.46" upper_limit="0.00"/>
                    <measurement group_id="O4" value="-0.89" lower_limit="-1.54" upper_limit="-0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Month 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.49" lower_limit="-2.32" upper_limit="-0.66"/>
                    <measurement group_id="O2" value="-2.22" lower_limit="-3.75" upper_limit="-0.69"/>
                    <measurement group_id="O3" value="-0.96" lower_limit="-1.75" upper_limit="-0.17"/>
                    <measurement group_id="O4" value="-1.22" lower_limit="-1.93" upper_limit="-0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Month 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.02" lower_limit="-1.78" upper_limit="-0.26"/>
                    <measurement group_id="O2" value="-1.95" lower_limit="-3.35" upper_limit="-0.55"/>
                    <measurement group_id="O3" value="-0.84" lower_limit="-1.56" upper_limit="-0.12"/>
                    <measurement group_id="O4" value="-1.07" lower_limit="-1.71" upper_limit="-0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Quality of Life as Assessed by the FACT-P : Additional Concerns</title>
        <description>The FACT-P is a multidimensional, self-report quality of life (QoL) instrument specifically designed for use with prostate cancer patients. It consists of 27 core items which assess patient function in four domains: Physical, Social/Family, Emotional, and Functional well-being, which is further supplemented by 12 site specific items to assess for prostate related symptoms. Each question is rated on a scale from 0 to 4, and then combined to produce sub-scale scores for each domain, as well as a global QoL score.
Additional concerns consist of 12 items and scored on a scale of 0-4 (0=Not at all; 1=A little bit; 2=Somewhat; 3=Quite a bit; 4=Very much). Total score for the additional concerns ranges from 0 to 48. Higher scores represent better QoL.</description>
        <time_frame>During 14 months</time_frame>
        <population>Analysis set consist of Full Phase B Analysis Set, which comprised of patients who completed 7 months of treatment and had a PSA ≤2.0 ng/mL at the end of Month 7 and had at least one primary endpoint efficacy assessment after Month 7.</population>
        <group_list>
          <group group_id="O1">
            <title>DI (Degarelix Intermittent)</title>
            <description>Patients in this arm received degarelix with a starting dose of 240 mg at a concentration of 40 mg/mL on Day 0 (Visit 1) administered subcutaneously (s.c.) into the anterior abdominal wall via two equivalent injections of 120 mg (3 mL) each.
Six maintenance doses of degarelix 80 mg per month at a concentration of 20 mg/mL (4 mL) at Days 28 to 168 (Visit 2 through 7), administered s.c. into the anterior abdominal wall.
During Phase B of the trial, If a patient had Prostate Specific Antigen (PSA) ≥2 ng/mL at any visit, additional doses of degarelix 240 mg followed by 80 mg maintenance dose(s) were administered.
Degarelix: Degarelix treatment provided for first seven months (one starting dose and six maintenance doses) followed by no treatment for next seven months period.</description>
          </group>
          <group group_id="O2">
            <title>DC (Degarelix Continuous)</title>
            <description>Patients in this arm received degarelix with a starting dose of 240 mg at a concentration of 40 mg/mL administered on Day 0 (Visit 1) s.c. into the anterior abdominal wall via two equivalent injections of 120 mg (3 mL) each.
Thirteen maintenance doses of degarelix 80 mg per month at a concentration of 20 mg/mL (4 mL) at Days 28 to 364, administered s.c. into the anterior abdominal wall.
Degarelix: Degarelix treatment provided for complete study period (one starting dose and 13 maintenance doses).</description>
          </group>
          <group group_id="O3">
            <title>LC (Leuprolide Continuous)</title>
            <description>Patients in this arm received leuprolide 7.5 mg one-month depot injection on Day 0 (Visit 1), administered intramuscular (i.m.) into a large muscle, as per manufacturer’s labeling directions.
One injection of 22.5 mg leuprolide 3-month depot was administered i.m. into a large muscle, according to the directions for use in the manufacturer’s labeling at Day 28 and every 3 months afterwards for 4 additional doses (i.e at Days 112, 196, 280, and 364, respectively).
On Investigator’s discretion, patients in the arm could take bicalutamide (Casodex®) for a maximum of 28 days to alleviate increased signs and symptoms due to initial upsurge in testosterone levels.
Leuprolide: Leuprolide treatment for complete study period (one starting dose and 5 maintenance doses of 3-month depot each).</description>
          </group>
          <group group_id="O4">
            <title>Total Continuous</title>
            <description>This is the combination of degarelix continuous and leuprolide continuous treatment arms.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Quality of Life as Assessed by the FACT-P : Additional Concerns</title>
          <description>The FACT-P is a multidimensional, self-report quality of life (QoL) instrument specifically designed for use with prostate cancer patients. It consists of 27 core items which assess patient function in four domains: Physical, Social/Family, Emotional, and Functional well-being, which is further supplemented by 12 site specific items to assess for prostate related symptoms. Each question is rated on a scale from 0 to 4, and then combined to produce sub-scale scores for each domain, as well as a global QoL score.
Additional concerns consist of 12 items and scored on a scale of 0-4 (0=Not at all; 1=A little bit; 2=Somewhat; 3=Quite a bit; 4=Very much). Total score for the additional concerns ranges from 0 to 48. Higher scores represent better QoL.</description>
          <population>Analysis set consist of Full Phase B Analysis Set, which comprised of patients who completed 7 months of treatment and had a PSA ≤2.0 ng/mL at the end of Month 7 and had at least one primary endpoint efficacy assessment after Month 7.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="150"/>
                <count group_id="O4" value="191"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Phase A, Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.14" lower_limit="-1.96" upper_limit="-0.32"/>
                    <measurement group_id="O2" value="-0.92" lower_limit="-2.42" upper_limit="0.57"/>
                    <measurement group_id="O3" value="-0.51" lower_limit="-1.30" upper_limit="0.27"/>
                    <measurement group_id="O4" value="-0.60" lower_limit="-1.29" upper_limit="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase A, Month 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.89" lower_limit="-1.71" upper_limit="-0.07"/>
                    <measurement group_id="O2" value="-1.34" lower_limit="-2.83" upper_limit="0.16"/>
                    <measurement group_id="O3" value="-1.03" lower_limit="-1.81" upper_limit="-0.25"/>
                    <measurement group_id="O4" value="-1.10" lower_limit="-1.79" upper_limit="-0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Month 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.29" lower_limit="-2.10" upper_limit="-0.48"/>
                    <measurement group_id="O2" value="-1.03" lower_limit="-2.50" upper_limit="0.45"/>
                    <measurement group_id="O3" value="-0.63" lower_limit="-1.40" upper_limit="0.14"/>
                    <measurement group_id="O4" value="-0.72" lower_limit="-1.40" upper_limit="-0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.97" lower_limit="-1.83" upper_limit="-0.11"/>
                    <measurement group_id="O2" value="-1.64" lower_limit="-3.20" upper_limit="-0.07"/>
                    <measurement group_id="O3" value="-0.90" lower_limit="-1.72" upper_limit="-0.08"/>
                    <measurement group_id="O4" value="-1.06" lower_limit="-1.79" upper_limit="-0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Month 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.86" lower_limit="-1.73" upper_limit="0.01"/>
                    <measurement group_id="O2" value="-0.80" lower_limit="-2.39" upper_limit="0.78"/>
                    <measurement group_id="O3" value="-0.70" lower_limit="-1.52" upper_limit="0.13"/>
                    <measurement group_id="O4" value="-0.72" lower_limit="-1.45" upper_limit="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Month 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.80" lower_limit="-1.62" upper_limit="0.01"/>
                    <measurement group_id="O2" value="-0.56" lower_limit="-2.05" upper_limit="0.92"/>
                    <measurement group_id="O3" value="-0.58" lower_limit="-1.35" upper_limit="0.20"/>
                    <measurement group_id="O4" value="-0.57" lower_limit="-1.26" upper_limit="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.75" lower_limit="-1.60" upper_limit="0.10"/>
                    <measurement group_id="O2" value="-1.20" lower_limit="-2.75" upper_limit="0.35"/>
                    <measurement group_id="O3" value="-0.75" lower_limit="-1.56" upper_limit="0.06"/>
                    <measurement group_id="O4" value="-0.84" lower_limit="-1.56" upper_limit="-0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Month 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.91" lower_limit="-1.75" upper_limit="-0.08"/>
                    <measurement group_id="O2" value="-0.96" lower_limit="-2.47" upper_limit="0.56"/>
                    <measurement group_id="O3" value="-0.86" lower_limit="-1.65" upper_limit="-0.06"/>
                    <measurement group_id="O4" value="-0.88" lower_limit="-1.58" upper_limit="-0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Month 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.81" lower_limit="-1.69" upper_limit="0.06"/>
                    <measurement group_id="O2" value="-0.67" lower_limit="-2.26" upper_limit="0.92"/>
                    <measurement group_id="O3" value="-0.27" lower_limit="-1.10" upper_limit="0.57"/>
                    <measurement group_id="O4" value="-0.35" lower_limit="-1.09" upper_limit="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Quality of Life as Assessed by the FACT-P: Total FACT-P Score</title>
        <description>The FACT-P is a multidimensional, self-report quality of life (QoL) instrument specifically designed for use with prostate cancer patients. It consists of 27 core items which assess patient function in four domains: Physical, Social/Family, Emotional, and Functional well-being, which is further supplemented by 12 site specific items to assess for prostate related symptoms. Each question is rated on a scale from 0 to 4, and then combined to produce sub-scale scores for each domain, as well as a global QoL score. Total FACT-P scores ranges from 0 to 156. Higher scores represent better QoL.</description>
        <time_frame>During 14 months</time_frame>
        <population>Analysis set consist of Full Phase B Analysis Set, which comprised of patients who completed 7 months of treatment and had a PSA ≤2.0 ng/mL at the end of Month 7 and had at least one primary endpoint efficacy assessment after Month 7.</population>
        <group_list>
          <group group_id="O1">
            <title>DI (Degarelix Intermittent)</title>
            <description>Patients in this arm received degarelix with a starting dose of 240 mg at a concentration of 40 mg/mL on Day 0 (Visit 1) administered subcutaneously (s.c.) into the anterior abdominal wall via two equivalent injections of 120 mg (3 mL) each.
Six maintenance doses of degarelix 80 mg per month at a concentration of 20 mg/mL (4 mL) at Days 28 to 168 (Visit 2 through 7), administered s.c. into the anterior abdominal wall.
During Phase B of the trial, If a patient had Prostate Specific Antigen (PSA) ≥2 ng/mL at any visit, additional doses of degarelix 240 mg followed by 80 mg maintenance dose(s) were administered.
Degarelix: Degarelix treatment provided for first seven months (one starting dose and six maintenance doses) followed by no treatment for next seven months period.</description>
          </group>
          <group group_id="O2">
            <title>DC (Degarelix Continuous)</title>
            <description>Patients in this arm received degarelix with a starting dose of 240 mg at a concentration of 40 mg/mL administered on Day 0 (Visit 1) s.c. into the anterior abdominal wall via two equivalent injections of 120 mg (3 mL) each.
Thirteen maintenance doses of degarelix 80 mg per month at a concentration of 20 mg/mL (4 mL) at Days 28 to 364, administered s.c. into the anterior abdominal wall.
Degarelix: Degarelix treatment provided for complete study period (one starting dose and 13 maintenance doses).</description>
          </group>
          <group group_id="O3">
            <title>LC (Leuprolide Continuous)</title>
            <description>Patients in this arm received leuprolide 7.5 mg one-month depot injection on Day 0 (Visit 1), administered intramuscular (i.m.) into a large muscle, as per manufacturer’s labeling directions.
One injection of 22.5 mg leuprolide 3-month depot was administered i.m. into a large muscle, according to the directions for use in the manufacturer’s labeling at Day 28 and every 3 months afterwards for 4 additional doses (i.e at Days 112, 196, 280, and 364, respectively).
On Investigator’s discretion, patients in the arm could take bicalutamide (Casodex®) for a maximum of 28 days to alleviate increased signs and symptoms due to initial upsurge in testosterone levels.
Leuprolide: Leuprolide treatment for complete study period (one starting dose and 5 maintenance doses of 3-month depot each).</description>
          </group>
          <group group_id="O4">
            <title>Total Continuous</title>
            <description>This is the combination of degarelix continuous and leuprolide continuous treatment arms.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Quality of Life as Assessed by the FACT-P: Total FACT-P Score</title>
          <description>The FACT-P is a multidimensional, self-report quality of life (QoL) instrument specifically designed for use with prostate cancer patients. It consists of 27 core items which assess patient function in four domains: Physical, Social/Family, Emotional, and Functional well-being, which is further supplemented by 12 site specific items to assess for prostate related symptoms. Each question is rated on a scale from 0 to 4, and then combined to produce sub-scale scores for each domain, as well as a global QoL score. Total FACT-P scores ranges from 0 to 156. Higher scores represent better QoL.</description>
          <population>Analysis set consist of Full Phase B Analysis Set, which comprised of patients who completed 7 months of treatment and had a PSA ≤2.0 ng/mL at the end of Month 7 and had at least one primary endpoint efficacy assessment after Month 7.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="150"/>
                <count group_id="O4" value="191"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Phase A, Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.86" lower_limit="-3.62" upper_limit="-0.10"/>
                    <measurement group_id="O2" value="-1.89" lower_limit="-5.13" upper_limit="1.34"/>
                    <measurement group_id="O3" value="-1.23" lower_limit="-2.92" upper_limit="0.45"/>
                    <measurement group_id="O4" value="-1.37" lower_limit="-2.87" upper_limit="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase A, Month 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.03" lower_limit="-3.87" upper_limit="-0.19"/>
                    <measurement group_id="O2" value="-2.64" lower_limit="-6.03" upper_limit="0.76"/>
                    <measurement group_id="O3" value="-2.38" lower_limit="-4.12" upper_limit="-0.63"/>
                    <measurement group_id="O4" value="-2.43" lower_limit="-3.98" upper_limit="-0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Month 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.75" lower_limit="-3.45" upper_limit="-0.04"/>
                    <measurement group_id="O2" value="-3.12" lower_limit="-6.26" upper_limit="0.03"/>
                    <measurement group_id="O3" value="-1.69" lower_limit="-3.31" upper_limit="-0.07"/>
                    <measurement group_id="O4" value="-1.99" lower_limit="-3.42" upper_limit="-0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.61" lower_limit="-3.46" upper_limit="0.23"/>
                    <measurement group_id="O2" value="-3.49" lower_limit="-6.89" upper_limit="-0.10"/>
                    <measurement group_id="O3" value="-2.84" lower_limit="-4.59" upper_limit="-1.09"/>
                    <measurement group_id="O4" value="-2.98" lower_limit="-4.53" upper_limit="-1.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Month 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.89" lower_limit="-2.84" upper_limit="1.05"/>
                    <measurement group_id="O2" value="-4.56" lower_limit="-8.15" upper_limit="-0.98"/>
                    <measurement group_id="O3" value="-3.16" lower_limit="-5.01" upper_limit="-1.31"/>
                    <measurement group_id="O4" value="-3.45" lower_limit="-5.09" upper_limit="-1.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Month 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.18" lower_limit="-3.10" upper_limit="0.73"/>
                    <measurement group_id="O2" value="-3.27" lower_limit="-6.79" upper_limit="0.26"/>
                    <measurement group_id="O3" value="-2.48" lower_limit="-4.30" upper_limit="-0.67"/>
                    <measurement group_id="O4" value="-2.65" lower_limit="-4.26" upper_limit="-1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.95" lower_limit="-2.88" upper_limit="0.98"/>
                    <measurement group_id="O2" value="-3.97" lower_limit="-7.52" upper_limit="-0.42"/>
                    <measurement group_id="O3" value="-1.60" lower_limit="-3.43" upper_limit="0.23"/>
                    <measurement group_id="O4" value="-2.09" lower_limit="-3.72" upper_limit="-0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Month 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.74" lower_limit="-3.72" upper_limit="0.24"/>
                    <measurement group_id="O2" value="-5.62" lower_limit="-9.26" upper_limit="-1.97"/>
                    <measurement group_id="O3" value="-1.85" lower_limit="-3.73" upper_limit="0.02"/>
                    <measurement group_id="O4" value="-2.64" lower_limit="-4.32" upper_limit="-0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Month 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.36" lower_limit="-3.24" upper_limit="0.52"/>
                    <measurement group_id="O2" value="-4.28" lower_limit="-7.75" upper_limit="-0.81"/>
                    <measurement group_id="O3" value="-1.65" lower_limit="-3.44" upper_limit="0.13"/>
                    <measurement group_id="O4" value="-2.20" lower_limit="-3.79" upper_limit="-0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Sexual Function as Assessed by the Sexual Function Index (SFI): Sexual Drive</title>
        <description>The SFI is a multidimensional, self-report instrument specifically designed to evaluate sexual function and satisfaction of men on treatment or with conditions that may affect sexual function. It consists of 11 questions which assess patient function in four domains: Sexual drive, Erection, Ejaculation, and Problem assessment, and a question in regards to overall assessment of sexual function.
Sexual drive domain consist of 2 questions and are scored on a scale of 0-4 (0=minimum, 4=maximum). Total score for the sexual drive domain ranges from 0 to 8. A higher scores represent better sexual function.</description>
        <time_frame>During 14 months</time_frame>
        <population>Analysis set consist of Full Phase B Analysis Set, which comprised of patients who completed 7 months of treatment and had a PSA ≤2.0 ng/mL at the end of Month 7 and had at least one primary endpoint efficacy assessment after Month 7.</population>
        <group_list>
          <group group_id="O1">
            <title>DI (Degarelix Intermittent)</title>
            <description>Patients in this arm received degarelix with a starting dose of 240 mg at a concentration of 40 mg/mL on Day 0 (Visit 1) administered subcutaneously (s.c.) into the anterior abdominal wall via two equivalent injections of 120 mg (3 mL) each.
Six maintenance doses of degarelix 80 mg per month at a concentration of 20 mg/mL (4 mL) at Days 28 to 168 (Visit 2 through 7), administered s.c. into the anterior abdominal wall.
During Phase B of the trial, If a patient had Prostate Specific Antigen (PSA) ≥2 ng/mL at any visit, additional doses of degarelix 240 mg followed by 80 mg maintenance dose(s) were administered.
Degarelix: Degarelix treatment provided for first seven months (one starting dose and six maintenance doses) followed by no treatment for next seven months period.</description>
          </group>
          <group group_id="O2">
            <title>DC (Degarelix Continuous)</title>
            <description>Patients in this arm received degarelix with a starting dose of 240 mg at a concentration of 40 mg/mL administered on Day 0 (Visit 1) s.c. into the anterior abdominal wall via two equivalent injections of 120 mg (3 mL) each.
Thirteen maintenance doses of degarelix 80 mg per month at a concentration of 20 mg/mL (4 mL) at Days 28 to 364, administered s.c. into the anterior abdominal wall.
Degarelix: Degarelix treatment provided for complete study period (one starting dose and 13 maintenance doses).</description>
          </group>
          <group group_id="O3">
            <title>LC (Leuprolide Continuous)</title>
            <description>Patients in this arm received leuprolide 7.5 mg one-month depot injection on Day 0 (Visit 1), administered intramuscular (i.m.) into a large muscle, as per manufacturer’s labeling directions.
One injection of 22.5 mg leuprolide 3-month depot was administered i.m. into a large muscle, according to the directions for use in the manufacturer’s labeling at Day 28 and every 3 months afterwards for 4 additional doses (i.e at Days 112, 196, 280, and 364, respectively).
On Investigator’s discretion, patients in the arm could take bicalutamide (Casodex®) for a maximum of 28 days to alleviate increased signs and symptoms due to initial upsurge in testosterone levels.
Leuprolide: Leuprolide treatment for complete study period (one starting dose and 5 maintenance doses of 3-month depot each).</description>
          </group>
          <group group_id="O4">
            <title>Total Continuous</title>
            <description>This is the combination of degarelix continuous and leuprolide continuous treatment arms.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Sexual Function as Assessed by the Sexual Function Index (SFI): Sexual Drive</title>
          <description>The SFI is a multidimensional, self-report instrument specifically designed to evaluate sexual function and satisfaction of men on treatment or with conditions that may affect sexual function. It consists of 11 questions which assess patient function in four domains: Sexual drive, Erection, Ejaculation, and Problem assessment, and a question in regards to overall assessment of sexual function.
Sexual drive domain consist of 2 questions and are scored on a scale of 0-4 (0=minimum, 4=maximum). Total score for the sexual drive domain ranges from 0 to 8. A higher scores represent better sexual function.</description>
          <population>Analysis set consist of Full Phase B Analysis Set, which comprised of patients who completed 7 months of treatment and had a PSA ≤2.0 ng/mL at the end of Month 7 and had at least one primary endpoint efficacy assessment after Month 7.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="150"/>
                <count group_id="O4" value="191"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Phase A, Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.57" lower_limit="-1.83" upper_limit="-1.32"/>
                    <measurement group_id="O2" value="-1.57" lower_limit="-2.04" upper_limit="-1.10"/>
                    <measurement group_id="O3" value="-1.27" lower_limit="-1.51" upper_limit="-1.03"/>
                    <measurement group_id="O4" value="-1.33" lower_limit="-1.55" upper_limit="-1.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase A, Month 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.71" lower_limit="-1.96" upper_limit="-1.47"/>
                    <measurement group_id="O2" value="-1.39" lower_limit="-1.84" upper_limit="-0.94"/>
                    <measurement group_id="O3" value="-1.67" lower_limit="-1.90" upper_limit="-1.44"/>
                    <measurement group_id="O4" value="-1.61" lower_limit="-1.82" upper_limit="-1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.72" lower_limit="-1.98" upper_limit="-1.46"/>
                    <measurement group_id="O2" value="-1.51" lower_limit="-1.99" upper_limit="-1.02"/>
                    <measurement group_id="O3" value="-1.62" lower_limit="-1.87" upper_limit="-1.37"/>
                    <measurement group_id="O4" value="-1.60" lower_limit="-1.82" upper_limit="-1.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Month 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.59" lower_limit="-1.85" upper_limit="-1.34"/>
                    <measurement group_id="O2" value="-1.52" lower_limit="-1.99" upper_limit="-1.05"/>
                    <measurement group_id="O3" value="-1.65" lower_limit="-1.89" upper_limit="-1.42"/>
                    <measurement group_id="O4" value="-1.63" lower_limit="-1.84" upper_limit="-1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Month 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.44" lower_limit="-1.69" upper_limit="-1.19"/>
                    <measurement group_id="O2" value="-1.55" lower_limit="-2.02" upper_limit="-1.08"/>
                    <measurement group_id="O3" value="-1.72" lower_limit="-1.96" upper_limit="-1.48"/>
                    <measurement group_id="O4" value="-1.69" lower_limit="-1.90" upper_limit="-1.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Month 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.30" lower_limit="-1.55" upper_limit="-1.04"/>
                    <measurement group_id="O2" value="-1.65" lower_limit="-2.12" upper_limit="-1.17"/>
                    <measurement group_id="O3" value="-1.72" lower_limit="-1.96" upper_limit="-1.48"/>
                    <measurement group_id="O4" value="-1.71" lower_limit="-1.92" upper_limit="-1.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Sexual Function as Assessed by the SFI: Erection</title>
        <description>The SFI is a multidimensional, self-report instrument specifically designed to evaluate sexual function and satisfaction of men on treatment or with conditions that may affect sexual function. It consists of 11 questions which assess patient function in four domains: Sexual drive, Erection, Ejaculation, and Problem assessment, and a question in regards to overall assessment of sexual function.
Erection domain consist of 3 questions and are scored on a scale of 0-4 (0=minimum, 4=maximum). Total score for the erection domain ranges from 0 to 12. A higher scores represent better sexual function.</description>
        <time_frame>During 14 months</time_frame>
        <population>Analysis set consist of Full Phase B Analysis Set, which comprised of patients who completed 7 months of treatment and had a PSA ≤2.0 ng/mL at the end of Month 7 and had at least one primary endpoint efficacy assessment after Month 7.</population>
        <group_list>
          <group group_id="O1">
            <title>DI (Degarelix Intermittent)</title>
            <description>Patients in this arm received degarelix with a starting dose of 240 mg at a concentration of 40 mg/mL on Day 0 (Visit 1) administered subcutaneously (s.c.) into the anterior abdominal wall via two equivalent injections of 120 mg (3 mL) each.
Six maintenance doses of degarelix 80 mg per month at a concentration of 20 mg/mL (4 mL) at Days 28 to 168 (Visit 2 through 7), administered s.c. into the anterior abdominal wall.
During Phase B of the trial, If a patient had Prostate Specific Antigen (PSA) ≥2 ng/mL at any visit, additional doses of degarelix 240 mg followed by 80 mg maintenance dose(s) were administered.
Degarelix: Degarelix treatment provided for first seven months (one starting dose and six maintenance doses) followed by no treatment for next seven months period.</description>
          </group>
          <group group_id="O2">
            <title>DC (Degarelix Continuous)</title>
            <description>Patients in this arm received degarelix with a starting dose of 240 mg at a concentration of 40 mg/mL administered on Day 0 (Visit 1) s.c. into the anterior abdominal wall via two equivalent injections of 120 mg (3 mL) each.
Thirteen maintenance doses of degarelix 80 mg per month at a concentration of 20 mg/mL (4 mL) at Days 28 to 364, administered s.c. into the anterior abdominal wall.
Degarelix: Degarelix treatment provided for complete study period (one starting dose and 13 maintenance doses).</description>
          </group>
          <group group_id="O3">
            <title>LC (Leuprolide Continuous)</title>
            <description>Patients in this arm received leuprolide 7.5 mg one-month depot injection on Day 0 (Visit 1), administered intramuscular (i.m.) into a large muscle, as per manufacturer’s labeling directions.
One injection of 22.5 mg leuprolide 3-month depot was administered i.m. into a large muscle, according to the directions for use in the manufacturer’s labeling at Day 28 and every 3 months afterwards for 4 additional doses (i.e at Days 112, 196, 280, and 364, respectively).
On Investigator’s discretion, patients in the arm could take bicalutamide (Casodex®) for a maximum of 28 days to alleviate increased signs and symptoms due to initial upsurge in testosterone levels.
Leuprolide: Leuprolide treatment for complete study period (one starting dose and 5 maintenance doses of 3-month depot each).</description>
          </group>
          <group group_id="O4">
            <title>Total Continuous</title>
            <description>This is the combination of degarelix continuous and leuprolide continuous treatment arms.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Sexual Function as Assessed by the SFI: Erection</title>
          <description>The SFI is a multidimensional, self-report instrument specifically designed to evaluate sexual function and satisfaction of men on treatment or with conditions that may affect sexual function. It consists of 11 questions which assess patient function in four domains: Sexual drive, Erection, Ejaculation, and Problem assessment, and a question in regards to overall assessment of sexual function.
Erection domain consist of 3 questions and are scored on a scale of 0-4 (0=minimum, 4=maximum). Total score for the erection domain ranges from 0 to 12. A higher scores represent better sexual function.</description>
          <population>Analysis set consist of Full Phase B Analysis Set, which comprised of patients who completed 7 months of treatment and had a PSA ≤2.0 ng/mL at the end of Month 7 and had at least one primary endpoint efficacy assessment after Month 7.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="150"/>
                <count group_id="O4" value="191"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Phase A, Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.32" lower_limit="-1.62" upper_limit="-1.01"/>
                    <measurement group_id="O2" value="-0.91" lower_limit="-1.48" upper_limit="-0.35"/>
                    <measurement group_id="O3" value="-1.21" lower_limit="-1.50" upper_limit="-0.91"/>
                    <measurement group_id="O4" value="-1.14" lower_limit="-1.40" upper_limit="-0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase A, Month 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.43" lower_limit="-1.75" upper_limit="-1.11"/>
                    <measurement group_id="O2" value="-1.06" lower_limit="-1.65" upper_limit="-0.47"/>
                    <measurement group_id="O3" value="-1.34" lower_limit="-1.65" upper_limit="-1.03"/>
                    <measurement group_id="O4" value="-1.28" lower_limit="-1.55" upper_limit="-1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.52" lower_limit="-1.80" upper_limit="-1.23"/>
                    <measurement group_id="O2" value="-1.07" lower_limit="-1.60" upper_limit="-0.54"/>
                    <measurement group_id="O3" value="-1.46" lower_limit="-1.74" upper_limit="-1.19"/>
                    <measurement group_id="O4" value="-1.38" lower_limit="-1.62" upper_limit="-1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Month 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.15" lower_limit="-1.44" upper_limit="-0.86"/>
                    <measurement group_id="O2" value="-1.34" lower_limit="-1.88" upper_limit="-0.80"/>
                    <measurement group_id="O3" value="-1.28" lower_limit="-1.56" upper_limit="-1.01"/>
                    <measurement group_id="O4" value="-1.30" lower_limit="-1.54" upper_limit="-1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Month 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.97" lower_limit="-1.30" upper_limit="-0.64"/>
                    <measurement group_id="O2" value="-1.36" lower_limit="-1.97" upper_limit="-0.74"/>
                    <measurement group_id="O3" value="-1.33" lower_limit="-1.65" upper_limit="-1.02"/>
                    <measurement group_id="O4" value="-1.34" lower_limit="-1.62" upper_limit="-1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Month 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.90" lower_limit="-1.25" upper_limit="-0.56"/>
                    <measurement group_id="O2" value="-1.43" lower_limit="-2.08" upper_limit="-0.79"/>
                    <measurement group_id="O3" value="-1.26" lower_limit="-1.59" upper_limit="-0.93"/>
                    <measurement group_id="O4" value="-1.29" lower_limit="-1.59" upper_limit="-1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Sexual Function as Assessed by the SFI: Ejaculation</title>
        <description>The SFI is a multidimensional, self-report instrument specifically designed to evaluate sexual function and satisfaction of men on treatment or with conditions that may affect sexual function. It consists of 11 questions which assess patient function in four domains: Sexual drive, Erection, Ejaculation, and Problem assessment, and a question in regards to overall assessment of sexual function.
Ejaculation domain consist of 2 questions and are scored on a scale of 0-4 (0=minimum, 4=maximum). Total score for the ejaculation domain ranges from 0 to 8. A higher scores represent better sexual function.</description>
        <time_frame>During 14 months</time_frame>
        <population>Analysis set consist of Full Phase B Analysis Set, which comprised of patients who completed 7 months of treatment and had a PSA ≤2.0 ng/mL at the end of Month 7 and had at least one primary endpoint efficacy assessment after Month 7.</population>
        <group_list>
          <group group_id="O1">
            <title>DI (Degarelix Intermittent)</title>
            <description>Patients in this arm received degarelix with a starting dose of 240 mg at a concentration of 40 mg/mL on Day 0 (Visit 1) administered subcutaneously (s.c.) into the anterior abdominal wall via two equivalent injections of 120 mg (3 mL) each.
Six maintenance doses of degarelix 80 mg per month at a concentration of 20 mg/mL (4 mL) at Days 28 to 168 (Visit 2 through 7), administered s.c. into the anterior abdominal wall.
During Phase B of the trial, If a patient had Prostate Specific Antigen (PSA) ≥2 ng/mL at any visit, additional doses of degarelix 240 mg followed by 80 mg maintenance dose(s) were administered.
Degarelix: Degarelix treatment provided for first seven months (one starting dose and six maintenance doses) followed by no treatment for next seven months period.</description>
          </group>
          <group group_id="O2">
            <title>DC (Degarelix Continuous)</title>
            <description>Patients in this arm received degarelix with a starting dose of 240 mg at a concentration of 40 mg/mL administered on Day 0 (Visit 1) s.c. into the anterior abdominal wall via two equivalent injections of 120 mg (3 mL) each.
Thirteen maintenance doses of degarelix 80 mg per month at a concentration of 20 mg/mL (4 mL) at Days 28 to 364, administered s.c. into the anterior abdominal wall.
Degarelix: Degarelix treatment provided for complete study period (one starting dose and 13 maintenance doses).</description>
          </group>
          <group group_id="O3">
            <title>LC (Leuprolide Continuous)</title>
            <description>Patients in this arm received leuprolide 7.5 mg one-month depot injection on Day 0 (Visit 1), administered intramuscular (i.m.) into a large muscle, as per manufacturer’s labeling directions.
One injection of 22.5 mg leuprolide 3-month depot was administered i.m. into a large muscle, according to the directions for use in the manufacturer’s labeling at Day 28 and every 3 months afterwards for 4 additional doses (i.e at Days 112, 196, 280, and 364, respectively).
On Investigator’s discretion, patients in the arm could take bicalutamide (Casodex®) for a maximum of 28 days to alleviate increased signs and symptoms due to initial upsurge in testosterone levels.
Leuprolide: Leuprolide treatment for complete study period (one starting dose and 5 maintenance doses of 3-month depot each).</description>
          </group>
          <group group_id="O4">
            <title>Total Continuous</title>
            <description>This is the combination of degarelix continuous and leuprolide continuous treatment arms.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Sexual Function as Assessed by the SFI: Ejaculation</title>
          <description>The SFI is a multidimensional, self-report instrument specifically designed to evaluate sexual function and satisfaction of men on treatment or with conditions that may affect sexual function. It consists of 11 questions which assess patient function in four domains: Sexual drive, Erection, Ejaculation, and Problem assessment, and a question in regards to overall assessment of sexual function.
Ejaculation domain consist of 2 questions and are scored on a scale of 0-4 (0=minimum, 4=maximum). Total score for the ejaculation domain ranges from 0 to 8. A higher scores represent better sexual function.</description>
          <population>Analysis set consist of Full Phase B Analysis Set, which comprised of patients who completed 7 months of treatment and had a PSA ≤2.0 ng/mL at the end of Month 7 and had at least one primary endpoint efficacy assessment after Month 7.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="150"/>
                <count group_id="O4" value="191"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Phase A, Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.04" lower_limit="-1.33" upper_limit="-0.75"/>
                    <measurement group_id="O2" value="-0.90" lower_limit="-1.43" upper_limit="-0.37"/>
                    <measurement group_id="O3" value="-0.87" lower_limit="-1.15" upper_limit="-0.59"/>
                    <measurement group_id="O4" value="-0.88" lower_limit="-1.13" upper_limit="-0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase A, Month 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.23" lower_limit="-1.48" upper_limit="-0.97"/>
                    <measurement group_id="O2" value="-0.80" lower_limit="-1.27" upper_limit="-0.34"/>
                    <measurement group_id="O3" value="-1.08" lower_limit="-1.32" upper_limit="-0.84"/>
                    <measurement group_id="O4" value="-1.02" lower_limit="-1.23" upper_limit="-0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.24" lower_limit="-1.51" upper_limit="-0.98"/>
                    <measurement group_id="O2" value="-1.06" lower_limit="-1.55" upper_limit="-0.57"/>
                    <measurement group_id="O3" value="-0.94" lower_limit="-1.20" upper_limit="-0.69"/>
                    <measurement group_id="O4" value="-0.97" lower_limit="-1.20" upper_limit="-0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Month 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.94" lower_limit="-1.22" upper_limit="-0.67"/>
                    <measurement group_id="O2" value="-1.24" lower_limit="-1.74" upper_limit="-0.74"/>
                    <measurement group_id="O3" value="-0.93" lower_limit="-1.19" upper_limit="-0.67"/>
                    <measurement group_id="O4" value="-1.00" lower_limit="-1.23" upper_limit="-0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Month 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.89" lower_limit="-1.15" upper_limit="-0.62"/>
                    <measurement group_id="O2" value="-1.07" lower_limit="-1.56" upper_limit="-0.58"/>
                    <measurement group_id="O3" value="-1.12" lower_limit="-1.38" upper_limit="-0.87"/>
                    <measurement group_id="O4" value="-1.11" lower_limit="-1.34" upper_limit="-0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Month 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.79" lower_limit="-1.10" upper_limit="-0.48"/>
                    <measurement group_id="O2" value="-1.17" lower_limit="-1.73" upper_limit="-0.61"/>
                    <measurement group_id="O3" value="-0.97" lower_limit="-1.27" upper_limit="-0.68"/>
                    <measurement group_id="O4" value="-1.01" lower_limit="-1.27" upper_limit="-0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Sexual Function as Assessed by the SFI: Problem Assessment</title>
        <description>The SFI is a multidimensional, self-report instrument specifically designed to evaluate sexual function and satisfaction of men on treatment or with conditions that may affect sexual function. It consists of 11 questions which assess patient function in four domains: Sexual drive, Erection, Ejaculation, and Problem assessment, and a question in regards to overall assessment of sexual function.
Problem assessment domain consist of 2 questions and are scored on a scale of 0-4 (0=minimum, 4=maximum). Total score for the problem assessment domain ranges from 0 to 8. A higher scores represent better sexual function.</description>
        <time_frame>During 14 months</time_frame>
        <population>Analysis set consist of Full Phase B Analysis Set, which comprised of patients who completed 7 months of treatment and had a PSA ≤2.0 ng/mL at the end of Month 7 and had at least one primary endpoint efficacy assessment after Month 7.</population>
        <group_list>
          <group group_id="O1">
            <title>DI (Degarelix Intermittent)</title>
            <description>Patients in this arm received degarelix with a starting dose of 240 mg at a concentration of 40 mg/mL on Day 0 (Visit 1) administered subcutaneously (s.c.) into the anterior abdominal wall via two equivalent injections of 120 mg (3 mL) each.
Six maintenance doses of degarelix 80 mg per month at a concentration of 20 mg/mL (4 mL) at Days 28 to 168 (Visit 2 through 7), administered s.c. into the anterior abdominal wall.
During Phase B of the trial, If a patient had Prostate Specific Antigen (PSA) ≥2 ng/mL at any visit, additional doses of degarelix 240 mg followed by 80 mg maintenance dose(s) were administered.
Degarelix: Degarelix treatment provided for first seven months (one starting dose and six maintenance doses) followed by no treatment for next seven months period.</description>
          </group>
          <group group_id="O2">
            <title>DC (Degarelix Continuous)</title>
            <description>Patients in this arm received degarelix with a starting dose of 240 mg at a concentration of 40 mg/mL administered on Day 0 (Visit 1) s.c. into the anterior abdominal wall via two equivalent injections of 120 mg (3 mL) each.
Thirteen maintenance doses of degarelix 80 mg per month at a concentration of 20 mg/mL (4 mL) at Days 28 to 364, administered s.c. into the anterior abdominal wall.
Degarelix: Degarelix treatment provided for complete study period (one starting dose and 13 maintenance doses).</description>
          </group>
          <group group_id="O3">
            <title>LC (Leuprolide Continuous)</title>
            <description>Patients in this arm received leuprolide 7.5 mg one-month depot injection on Day 0 (Visit 1), administered intramuscular (i.m.) into a large muscle, as per manufacturer’s labeling directions.
One injection of 22.5 mg leuprolide 3-month depot was administered i.m. into a large muscle, according to the directions for use in the manufacturer’s labeling at Day 28 and every 3 months afterwards for 4 additional doses (i.e at Days 112, 196, 280, and 364, respectively).
On Investigator’s discretion, patients in the arm could take bicalutamide (Casodex®) for a maximum of 28 days to alleviate increased signs and symptoms due to initial upsurge in testosterone levels.
Leuprolide: Leuprolide treatment for complete study period (one starting dose and 5 maintenance doses of 3-month depot each).</description>
          </group>
          <group group_id="O4">
            <title>Total Continuous</title>
            <description>This is the combination of degarelix continuous and leuprolide continuous treatment arms.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Sexual Function as Assessed by the SFI: Problem Assessment</title>
          <description>The SFI is a multidimensional, self-report instrument specifically designed to evaluate sexual function and satisfaction of men on treatment or with conditions that may affect sexual function. It consists of 11 questions which assess patient function in four domains: Sexual drive, Erection, Ejaculation, and Problem assessment, and a question in regards to overall assessment of sexual function.
Problem assessment domain consist of 2 questions and are scored on a scale of 0-4 (0=minimum, 4=maximum). Total score for the problem assessment domain ranges from 0 to 8. A higher scores represent better sexual function.</description>
          <population>Analysis set consist of Full Phase B Analysis Set, which comprised of patients who completed 7 months of treatment and had a PSA ≤2.0 ng/mL at the end of Month 7 and had at least one primary endpoint efficacy assessment after Month 7.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="150"/>
                <count group_id="O4" value="191"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Phase A, Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.26" lower_limit="-0.93" upper_limit="0.41"/>
                    <measurement group_id="O2" value="-0.58" lower_limit="-1.82" upper_limit="0.66"/>
                    <measurement group_id="O3" value="-0.36" lower_limit="-1.00" upper_limit="0.28"/>
                    <measurement group_id="O4" value="-0.40" lower_limit="-0.97" upper_limit="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase A, Month 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.90" lower_limit="-1.60" upper_limit="-0.19"/>
                    <measurement group_id="O2" value="-0.88" lower_limit="-2.19" upper_limit="0.44"/>
                    <measurement group_id="O3" value="-0.57" lower_limit="-1.25" upper_limit="0.11"/>
                    <measurement group_id="O4" value="-0.63" lower_limit="-1.23" upper_limit="-0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.56" lower_limit="-1.30" upper_limit="0.17"/>
                    <measurement group_id="O2" value="-0.71" lower_limit="-2.07" upper_limit="0.65"/>
                    <measurement group_id="O3" value="-0.64" lower_limit="-1.34" upper_limit="0.06"/>
                    <measurement group_id="O4" value="-0.66" lower_limit="-1.28" upper_limit="-0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Month 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" lower_limit="-0.65" upper_limit="0.83"/>
                    <measurement group_id="O2" value="-0.53" lower_limit="-1.90" upper_limit="0.84"/>
                    <measurement group_id="O3" value="-0.98" lower_limit="-1.68" upper_limit="-0.27"/>
                    <measurement group_id="O4" value="-0.89" lower_limit="-1.51" upper_limit="-0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Month 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.15" lower_limit="-0.88" upper_limit="0.58"/>
                    <measurement group_id="O2" value="-1.63" lower_limit="-2.99" upper_limit="-0.27"/>
                    <measurement group_id="O3" value="-1.07" lower_limit="-1.77" upper_limit="-0.38"/>
                    <measurement group_id="O4" value="-1.19" lower_limit="-1.81" upper_limit="-0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Month 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.31" lower_limit="-1.04" upper_limit="0.41"/>
                    <measurement group_id="O2" value="-1.68" lower_limit="-3.03" upper_limit="-0.33"/>
                    <measurement group_id="O3" value="-0.89" lower_limit="-1.58" upper_limit="-0.19"/>
                    <measurement group_id="O4" value="-1.05" lower_limit="-1.67" upper_limit="-0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Sexual Function as Assessed by the SFI: Overall Satisfaction With Sex Life</title>
        <description>The SFI is a multidimensional, self-report instrument specifically designed to evaluate sexual function and satisfaction of men on treatment or with conditions that may affect sexual function. It consists of 11 questions which assess patient function in four domains: Sexual drive, Erection, Ejaculation, and Problem assessment, and a question in regards to overall assessment of sexual function.
Overall satisfaction domain consist of single question and is scored on a scale of 0-4 (0=minimum, 4=maximum). A higher score represent better sexual function.</description>
        <time_frame>During 14 months</time_frame>
        <population>Analysis set consist of Full Phase B Analysis Set, which comprised of patients who completed 7 months of treatment and had a PSA ≤2.0 ng/mL at the end of Month 7 and had at least one primary endpoint efficacy assessment after Month 7.</population>
        <group_list>
          <group group_id="O1">
            <title>DI (Degarelix Intermittent)</title>
            <description>Patients in this arm received degarelix with a starting dose of 240 mg at a concentration of 40 mg/mL on Day 0 (Visit 1) administered subcutaneously (s.c.) into the anterior abdominal wall via two equivalent injections of 120 mg (3 mL) each.
Six maintenance doses of degarelix 80 mg per month at a concentration of 20 mg/mL (4 mL) at Days 28 to 168 (Visit 2 through 7), administered s.c. into the anterior abdominal wall.
During Phase B of the trial, If a patient had Prostate Specific Antigen (PSA) ≥2 ng/mL at any visit, additional doses of degarelix 240 mg followed by 80 mg maintenance dose(s) were administered.
Degarelix: Degarelix treatment provided for first seven months (one starting dose and six maintenance doses) followed by no treatment for next seven months period.</description>
          </group>
          <group group_id="O2">
            <title>DC (Degarelix Continuous)</title>
            <description>Patients in this arm received degarelix with a starting dose of 240 mg at a concentration of 40 mg/mL administered on Day 0 (Visit 1) s.c. into the anterior abdominal wall via two equivalent injections of 120 mg (3 mL) each.
Thirteen maintenance doses of degarelix 80 mg per month at a concentration of 20 mg/mL (4 mL) at Days 28 to 364, administered s.c. into the anterior abdominal wall.
Degarelix: Degarelix treatment provided for complete study period (one starting dose and 13 maintenance doses).</description>
          </group>
          <group group_id="O3">
            <title>LC (Leuprolide Continuous)</title>
            <description>Patients in this arm received leuprolide 7.5 mg one-month depot injection on Day 0 (Visit 1), administered intramuscular (i.m.) into a large muscle, as per manufacturer’s labeling directions.
One injection of 22.5 mg leuprolide 3-month depot was administered i.m. into a large muscle, according to the directions for use in the manufacturer’s labeling at Day 28 and every 3 months afterwards for 4 additional doses (i.e at Days 112, 196, 280, and 364, respectively).
On Investigator’s discretion, patients in the arm could take bicalutamide (Casodex®) for a maximum of 28 days to alleviate increased signs and symptoms due to initial upsurge in testosterone levels.
Leuprolide: Leuprolide treatment for complete study period (one starting dose and 5 maintenance doses of 3-month depot each).</description>
          </group>
          <group group_id="O4">
            <title>Total Continuous</title>
            <description>This is the combination of degarelix continuous and leuprolide continuous treatment arms.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Sexual Function as Assessed by the SFI: Overall Satisfaction With Sex Life</title>
          <description>The SFI is a multidimensional, self-report instrument specifically designed to evaluate sexual function and satisfaction of men on treatment or with conditions that may affect sexual function. It consists of 11 questions which assess patient function in four domains: Sexual drive, Erection, Ejaculation, and Problem assessment, and a question in regards to overall assessment of sexual function.
Overall satisfaction domain consist of single question and is scored on a scale of 0-4 (0=minimum, 4=maximum). A higher score represent better sexual function.</description>
          <population>Analysis set consist of Full Phase B Analysis Set, which comprised of patients who completed 7 months of treatment and had a PSA ≤2.0 ng/mL at the end of Month 7 and had at least one primary endpoint efficacy assessment after Month 7.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="150"/>
                <count group_id="O4" value="191"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Phase A, Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.32" lower_limit="-0.50" upper_limit="-0.13"/>
                    <measurement group_id="O2" value="-0.18" lower_limit="-0.53" upper_limit="0.16"/>
                    <measurement group_id="O3" value="-0.27" lower_limit="-0.45" upper_limit="-0.09"/>
                    <measurement group_id="O4" value="-0.25" lower_limit="-0.41" upper_limit="-0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase A, Month 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.28" lower_limit="-0.48" upper_limit="-0.07"/>
                    <measurement group_id="O2" value="-0.37" lower_limit="-0.74" upper_limit="0.01"/>
                    <measurement group_id="O3" value="-0.40" lower_limit="-0.59" upper_limit="-0.21"/>
                    <measurement group_id="O4" value="-0.39" lower_limit="-0.56" upper_limit="-0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.33" lower_limit="-0.53" upper_limit="-0.13"/>
                    <measurement group_id="O2" value="-0.34" lower_limit="-0.71" upper_limit="0.03"/>
                    <measurement group_id="O3" value="-0.41" lower_limit="-0.60" upper_limit="-0.22"/>
                    <measurement group_id="O4" value="-0.39" lower_limit="-0.56" upper_limit="-0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Month 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.15" lower_limit="-0.35" upper_limit="0.05"/>
                    <measurement group_id="O2" value="-0.47" lower_limit="-0.85" upper_limit="-0.09"/>
                    <measurement group_id="O3" value="-0.41" lower_limit="-0.60" upper_limit="-0.21"/>
                    <measurement group_id="O4" value="-0.42" lower_limit="-0.59" upper_limit="-0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Month 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.11" lower_limit="-0.32" upper_limit="0.09"/>
                    <measurement group_id="O2" value="-0.57" lower_limit="-0.95" upper_limit="-0.20"/>
                    <measurement group_id="O3" value="-0.42" lower_limit="-0.61" upper_limit="-0.23"/>
                    <measurement group_id="O4" value="-0.45" lower_limit="-0.62" upper_limit="-0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Month 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.12" lower_limit="-0.32" upper_limit="0.08"/>
                    <measurement group_id="O2" value="-0.70" lower_limit="-1.08" upper_limit="-0.33"/>
                    <measurement group_id="O3" value="-0.37" lower_limit="-0.57" upper_limit="-0.18"/>
                    <measurement group_id="O4" value="-0.44" lower_limit="-0.61" upper_limit="-0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Sexual Function as Assessed by the SFI: Total SFI Score</title>
        <description>The SFI is a multidimensional, self-report instrument specifically designed to evaluate sexual function and satisfaction of men on treatment or with conditions that may affect sexual function. It consists of 11 questions which assess patient function in four domains: Sexual drive, Erection, Ejaculation, and Problem assessment, and a question in regards to overall assessment of sexual function. Total SFI score ranges from 0 to 44. A higher scores represent better sexual function.</description>
        <time_frame>During 14 months</time_frame>
        <population>Analysis set consist of Full Phase B Analysis Set, which comprised of patients who completed 7 months of treatment and had a PSA ≤2.0 ng/mL at the end of Month 7 and had at least one primary endpoint efficacy assessment after Month 7.</population>
        <group_list>
          <group group_id="O1">
            <title>DI (Degarelix Intermittent)</title>
            <description>Patients in this arm received degarelix with a starting dose of 240 mg at a concentration of 40 mg/mL on Day 0 administered subcutaneously (s.c.) into the anterior abdominal wall via two equivalent injections of 120 mg (3 mL) each.
Six maintenance doses of degarelix 80 mg per month at a concentration of 20 mg/mL (4 mL) at Days 28 to 168 were administered.
During Phase B of the trial, If a patient had Prostate Specific Antigen (PSA) ≥2 ng/mL at any visit, additional doses of degarelix 240 mg followed by 80 mg maintenance dose(s) were administered.
Degarelix: Degarelix treatment provided for first seven months (one starting dose and six maintenance doses) followed by no treatment for next seven months period.</description>
          </group>
          <group group_id="O2">
            <title>DC (Degarelix Continuous)</title>
            <description>Patients in this arm received degarelix with a starting dose of 240 mg at a concentration of 40 mg/mL administered on Day 0 (Visit 1) s.c. into the anterior abdominal wall via two equivalent injections of 120 mg (3 mL) each.
Thirteen maintenance doses of degarelix 80 mg per month at a concentration of 20 mg/mL (4 mL) at Days 28 to 364, administered s.c. into the anterior abdominal wall.
Degarelix: Degarelix treatment provided for complete study period (one starting dose and 13 maintenance doses).</description>
          </group>
          <group group_id="O3">
            <title>LC (Leuprolide Continuous)</title>
            <description>Patients in this arm received leuprolide 7.5 mg one-month depot injection on Day 0 (Visit 1), administered intramuscular (i.m.) into a large muscle, as per manufacturer’s labeling directions.
One injection of 22.5 mg leuprolide 3-month depot was administered i.m. into a large muscle, according to the directions for use in the manufacturer’s labeling at Day 28 and every 3 months afterwards for 4 additional doses (i.e at Days 112, 196, 280, and 364, respectively).
On Investigator’s discretion, patients in the arm could take bicalutamide (Casodex®) for a maximum of 28 days to alleviate increased signs and symptoms due to initial upsurge in testosterone levels.
Leuprolide: Leuprolide treatment for complete study period (one starting dose and 5 maintenance doses of 3-month depot each).</description>
          </group>
          <group group_id="O4">
            <title>Total Continuous</title>
            <description>This is the combination of degarelix continuous and leuprolide continuous treatment arms.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Sexual Function as Assessed by the SFI: Total SFI Score</title>
          <description>The SFI is a multidimensional, self-report instrument specifically designed to evaluate sexual function and satisfaction of men on treatment or with conditions that may affect sexual function. It consists of 11 questions which assess patient function in four domains: Sexual drive, Erection, Ejaculation, and Problem assessment, and a question in regards to overall assessment of sexual function. Total SFI score ranges from 0 to 44. A higher scores represent better sexual function.</description>
          <population>Analysis set consist of Full Phase B Analysis Set, which comprised of patients who completed 7 months of treatment and had a PSA ≤2.0 ng/mL at the end of Month 7 and had at least one primary endpoint efficacy assessment after Month 7.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="150"/>
                <count group_id="O4" value="191"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Phase A, Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.07" lower_limit="-5.10" upper_limit="-3.05"/>
                    <measurement group_id="O2" value="-3.93" lower_limit="-5.84" upper_limit="-2.02"/>
                    <measurement group_id="O3" value="-3.69" lower_limit="-4.67" upper_limit="-2.71"/>
                    <measurement group_id="O4" value="-3.74" lower_limit="-4.61" upper_limit="-2.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase A, Month 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.20" lower_limit="-6.23" upper_limit="-4.16"/>
                    <measurement group_id="O2" value="-4.28" lower_limit="-6.21" upper_limit="-2.35"/>
                    <measurement group_id="O3" value="-4.57" lower_limit="-5.56" upper_limit="-3.58"/>
                    <measurement group_id="O4" value="-4.51" lower_limit="-5.38" upper_limit="-3.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.97" lower_limit="-6.04" upper_limit="-3.91"/>
                    <measurement group_id="O2" value="-4.35" lower_limit="-6.33" upper_limit="-2.37"/>
                    <measurement group_id="O3" value="-4.62" lower_limit="-5.63" upper_limit="-3.61"/>
                    <measurement group_id="O4" value="-4.56" lower_limit="-5.46" upper_limit="-3.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Month 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.56" lower_limit="-4.63" upper_limit="-2.49"/>
                    <measurement group_id="O2" value="-4.62" lower_limit="-6.62" upper_limit="-2.63"/>
                    <measurement group_id="O3" value="-4.74" lower_limit="-5.76" upper_limit="-3.72"/>
                    <measurement group_id="O4" value="-4.71" lower_limit="-5.62" upper_limit="-3.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Month 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.37" lower_limit="-4.48" upper_limit="-2.26"/>
                    <measurement group_id="O2" value="-5.59" lower_limit="-7.66" upper_limit="-3.52"/>
                    <measurement group_id="O3" value="-5.15" lower_limit="-6.21" upper_limit="-4.09"/>
                    <measurement group_id="O4" value="-5.24" lower_limit="-6.18" upper_limit="-4.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Month 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.27" lower_limit="-4.41" upper_limit="-2.12"/>
                    <measurement group_id="O2" value="-5.93" lower_limit="-8.06" upper_limit="-3.80"/>
                    <measurement group_id="O3" value="-4.68" lower_limit="-5.77" upper_limit="-3.59"/>
                    <measurement group_id="O4" value="-4.94" lower_limit="-5.91" upper_limit="-3.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With a Serum PSA Level ≤4.0 ng/mL</title>
        <description>Percentage of Subjects With a Serum PSA Level ≤4.0 ng/mL was measured during the study period.</description>
        <time_frame>At 14 months</time_frame>
        <population>Analysis set consist of Full Phase B Analysis Set, which comprised of patients who completed 7 months of treatment and had a PSA ≤2.0 ng/mL at the end of Month 7 and had at least one primary endpoint efficacy assessment after Month 7.</population>
        <group_list>
          <group group_id="O1">
            <title>DI (Degarelix Intermittent)</title>
            <description>Patients in this arm received degarelix with a starting dose of 240 mg at a concentration of 40 mg/mL on Day 0 (Visit 1) administered subcutaneously (s.c.) into the anterior abdominal wall via two equivalent injections of 120 mg (3 mL) each.
Six maintenance doses of degarelix 80 mg per month at a concentration of 20 mg/mL (4 mL) at Days 28 to 168 (Visit 2 through 7), administered s.c. into the anterior abdominal wall.
During Phase B of the trial, If a patient had Prostate Specific Antigen (PSA) ≥2 ng/mL at any visit, additional doses of degarelix 240 mg followed by 80 mg maintenance dose(s) were administered.
Degarelix: Degarelix treatment provided for first seven months (one starting dose and six maintenance doses) followed by no treatment for next seven months period.</description>
          </group>
          <group group_id="O2">
            <title>DC (Degarelix Continuous)</title>
            <description>Patients in this arm received degarelix with a starting dose of 240 mg at a concentration of 40 mg/mL administered on Day 0 (Visit 1) s.c. into the anterior abdominal wall via two equivalent injections of 120 mg (3 mL) each.
Thirteen maintenance doses of degarelix 80 mg per month at a concentration of 20 mg/mL (4 mL) at Days 28 to 364, administered s.c. into the anterior abdominal wall.
Degarelix: Degarelix treatment provided for complete study period (one starting dose and 13 maintenance doses).</description>
          </group>
          <group group_id="O3">
            <title>LC (Leuprolide Continuous)</title>
            <description>Patients in this arm received leuprolide 7.5 mg one-month depot injection on Day 0 (Visit 1), administered intramuscular (i.m.) into a large muscle, as per manufacturer’s labeling directions.
One injection of 22.5 mg leuprolide 3-month depot was administered i.m. into a large muscle, according to the directions for use in the manufacturer’s labeling at Day 28 and every 3 months afterwards for 4 additional doses (i.e at Days 112, 196, 280, and 364, respectively).
On Investigator’s discretion, patients in the arm could take bicalutamide (Casodex®) for a maximum of 28 days to alleviate increased signs and symptoms due to initial upsurge in testosterone levels.
Leuprolide: Leuprolide treatment for complete study period (one starting dose and 5 maintenance doses of 3-month depot each).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With a Serum PSA Level ≤4.0 ng/mL</title>
          <description>Percentage of Subjects With a Serum PSA Level ≤4.0 ng/mL was measured during the study period.</description>
          <population>Analysis set consist of Full Phase B Analysis Set, which comprised of patients who completed 7 months of treatment and had a PSA ≤2.0 ng/mL at the end of Month 7 and had at least one primary endpoint efficacy assessment after Month 7.</population>
          <units>Percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="97.3" upper_limit="100"/>
                    <measurement group_id="O2" value="97.6" lower_limit="87.1" upper_limit="99.9"/>
                    <measurement group_id="O3" value="98.7" lower_limit="95.3" upper_limit="99.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Return to Testosterone &gt;0.5 ng/mL Level in the DI Treatment Group</title>
        <description>The time to testosterone &gt;0.5 ng/mL level in the DI group was counted from the start of Phase B at Day 196 (i.e. 28 days after last injection of degarelix)</description>
        <time_frame>During Phase B</time_frame>
        <population>Analysis set consist of Full Phase B Analysis Set, which comprised of patients who completed 7 months of treatment and had a PSA ≤2.0 ng/mL at the end of Month 7 and had at least one primary endpoint efficacy assessment after Month 7.</population>
        <group_list>
          <group group_id="O1">
            <title>DI (Degarelix Intermittent)</title>
            <description>Patients in this arm received degarelix with a starting dose of 240 mg at a concentration of 40 mg/mL on Day 0 (Visit 1) administered subcutaneously (s.c.) into the anterior abdominal wall via two equivalent injections of 120 mg (3 mL) each.
Six maintenance doses of degarelix 80 mg per month at a concentration of 20 mg/mL (4 mL) at Days 28 to 168 (Visit 2 through 7), administered s.c. into the anterior abdominal wall.
During Phase B of the trial, If a patient had Prostate Specific Antigen (PSA) ≥2 ng/mL at any visit, additional doses of degarelix 240 mg followed by 80 mg maintenance dose(s) were administered.
Degarelix: Degarelix treatment provided for first seven months (one starting dose and six maintenance doses) followed by no treatment for next seven months period.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Return to Testosterone &gt;0.5 ng/mL Level in the DI Treatment Group</title>
          <description>The time to testosterone &gt;0.5 ng/mL level in the DI group was counted from the start of Phase B at Day 196 (i.e. 28 days after last injection of degarelix)</description>
          <population>Analysis set consist of Full Phase B Analysis Set, which comprised of patients who completed 7 months of treatment and had a PSA ≤2.0 ng/mL at the end of Month 7 and had at least one primary endpoint efficacy assessment after Month 7.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112.0" lower_limit="112.0" upper_limit="140.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Return to Normal Range (≥1.5 ng/mL) or Baseline Testosterone Level</title>
        <description>The time to return to normal range (≥1.5 ng/mL) or Baseline testosterone level in the DI group was counted from the start of Phase B at Day 196 (i.e. 28 days after last injection of degarelix).</description>
        <time_frame>During Phase B</time_frame>
        <population>Analysis set consist of Full Phase B Analysis Set, which comprised of patients who completed 7 months of treatment and had a PSA ≤2.0 ng/mL at the end of Month 7 and had at least one primary endpoint efficacy assessment after Month 7.</population>
        <group_list>
          <group group_id="O1">
            <title>DI (Degarelix Intermittent)</title>
            <description>Patients in this arm received degarelix with a starting dose of 240 mg at a concentration of 40 mg/mL on Day 0 (Visit 1) administered subcutaneously (s.c.) into the anterior abdominal wall via two equivalent injections of 120 mg (3 mL) each.
Six maintenance doses of degarelix 80 mg per month at a concentration of 20 mg/mL (4 mL) at Days 28 to 168 (Visit 2 through 7), administered s.c. into the anterior abdominal wall.
During Phase B of the trial, If a patient had Prostate Specific Antigen (PSA) ≥2 ng/mL at any visit, additional doses of degarelix 240 mg followed by 80 mg maintenance dose(s) were administered.
Degarelix: Degarelix treatment provided for first seven months (one starting dose and six maintenance doses) followed by no treatment for next seven months period.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Return to Normal Range (≥1.5 ng/mL) or Baseline Testosterone Level</title>
          <description>The time to return to normal range (≥1.5 ng/mL) or Baseline testosterone level in the DI group was counted from the start of Phase B at Day 196 (i.e. 28 days after last injection of degarelix).</description>
          <population>Analysis set consist of Full Phase B Analysis Set, which comprised of patients who completed 7 months of treatment and had a PSA ≤2.0 ng/mL at the end of Month 7 and had at least one primary endpoint efficacy assessment after Month 7.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="168" lower_limit="140.0" upper_limit="168.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in Serum Testosterone Levels</title>
        <description>Absolute Change From Baseline in Serum Testosterone Levels was measured.</description>
        <time_frame>Phase A Visit 1-8 and Phase B Visit 9-15.</time_frame>
        <population>Analysis set consist of Full Phase B Analysis Set, which comprised of patients who completed 7 months of treatment and had a PSA ≤2.0 ng/mL at the end of Month 7 and had at least one primary endpoint efficacy assessment after Month 7.</population>
        <group_list>
          <group group_id="O1">
            <title>DI (Degarelix Intermittent)</title>
            <description>Patients in this arm received degarelix with a starting dose of 240 mg at a concentration of 40 mg/mL on Day 0 (Visit 1) administered subcutaneously (s.c.) into the anterior abdominal wall via two equivalent injections of 120 mg (3 mL) each.
Six maintenance doses of degarelix 80 mg per month at a concentration of 20 mg/mL (4 mL) at Days 28 to 168 (Visit 2 through 7), administered s.c. into the anterior abdominal wall.
During Phase B of the trial, If a patient had Prostate Specific Antigen (PSA) ≥2 ng/mL at any visit, additional doses of degarelix 240 mg followed by 80 mg maintenance dose(s) were administered.
Degarelix: Degarelix treatment provided for first seven months (one starting dose and six maintenance doses) followed by no treatment for next seven months period.</description>
          </group>
          <group group_id="O2">
            <title>DC (Degarelix Continuous)</title>
            <description>Patients in this arm received degarelix with a starting dose of 240 mg at a concentration of 40 mg/mL administered on Day 0 (Visit 1) s.c. into the anterior abdominal wall via two equivalent injections of 120 mg (3 mL) each.
Thirteen maintenance doses of degarelix 80 mg per month at a concentration of 20 mg/mL (4 mL) at Days 28 to 364, administered s.c. into the anterior abdominal wall.
Degarelix: Degarelix treatment provided for complete study period (one starting dose and 13 maintenance doses).</description>
          </group>
          <group group_id="O3">
            <title>LC (Leuprolide Continuous)</title>
            <description>Patients in this arm received leuprolide 7.5 mg one-month depot injection on Day 0 (Visit 1), administered intramuscular (i.m.) into a large muscle, as per manufacturer’s labeling directions.
One injection of 22.5 mg leuprolide 3-month depot was administered i.m. into a large muscle, according to the directions for use in the manufacturer’s labeling at Day 28 and every 3 months afterwards for 4 additional doses (i.e at Days 112, 196, 280, and 364, respectively).
On Investigator’s discretion, patients in the arm could take bicalutamide (Casodex®) for a maximum of 28 days to alleviate increased signs and symptoms due to initial upsurge in testosterone levels.
Leuprolide: Leuprolide treatment for complete study period (one starting dose and 5 maintenance doses of 3-month depot each).</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in Serum Testosterone Levels</title>
          <description>Absolute Change From Baseline in Serum Testosterone Levels was measured.</description>
          <population>Analysis set consist of Full Phase B Analysis Set, which comprised of patients who completed 7 months of treatment and had a PSA ≤2.0 ng/mL at the end of Month 7 and had at least one primary endpoint efficacy assessment after Month 7.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Phase A, Visit 1 (Day 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">This visit was the first dosing visit. Serum samples were collected pre-dosing on this visit. Thus, the estimated value obtained on this visit were considered as Baseline value. Hence no change is reported.</measurement>
                    <measurement group_id="O2" value="-2.97">One patient erroneously received medication prior to this visit. Thus, the value obtained on this visit was considered as first post-baseline value for this patient and is reported. There was no SD.</measurement>
                    <measurement group_id="O3" value="NA">This visit was the first dosing visit. Serum samples were collected pre-dosing on this visit. Thus, the estimated value obtained on this visit were considered as Baseline value. Hence no change is reported.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase A, Visit 2 (Month 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.64" spread="1.4"/>
                    <measurement group_id="O2" value="-3.77" spread="1.43"/>
                    <measurement group_id="O3" value="-3.7" spread="1.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase A, Visit 3 (Month 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.67" spread="1.4"/>
                    <measurement group_id="O2" value="-3.77" spread="1.44"/>
                    <measurement group_id="O3" value="-3.77" spread="1.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase A, Visit 4 (Month 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.68" spread="1.4"/>
                    <measurement group_id="O2" value="-3.78" spread="1.43"/>
                    <measurement group_id="O3" value="-3.77" spread="1.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase A, Visit 5 (Month 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.67" spread="1.41"/>
                    <measurement group_id="O2" value="-3.78" spread="1.44"/>
                    <measurement group_id="O3" value="-3.74" spread="1.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase A, Visit 6 (Month 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.67" spread="1.41"/>
                    <measurement group_id="O2" value="-3.78" spread="1.44"/>
                    <measurement group_id="O3" value="-3.78" spread="1.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase A, Visit 7 (Month 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.66" spread="1.41"/>
                    <measurement group_id="O2" value="-3.77" spread="1.44"/>
                    <measurement group_id="O3" value="-3.77" spread="1.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase A, Visit 8 (Month 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.66" spread="1.42"/>
                    <measurement group_id="O2" value="-3.78" spread="1.43"/>
                    <measurement group_id="O3" value="-3.78" spread="1.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Visit 9 (Month 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.63" spread="1.44"/>
                    <measurement group_id="O2" value="-3.76" spread="1.44"/>
                    <measurement group_id="O3" value="-3.78" spread="1.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Visit 10 (Month 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.41" spread="1.6"/>
                    <measurement group_id="O2" value="-3.76" spread="1.44"/>
                    <measurement group_id="O3" value="-3.78" spread="1.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Visit 11 (Month 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.0" spread="1.76"/>
                    <measurement group_id="O2" value="-3.75" spread="1.44"/>
                    <measurement group_id="O3" value="-3.77" spread="1.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Visit 12 (Month 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.57" spread="1.78"/>
                    <measurement group_id="O2" value="-3.74" spread="1.43"/>
                    <measurement group_id="O3" value="-3.78" spread="1.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Visit 13 (Month 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.18" spread="1.8"/>
                    <measurement group_id="O2" value="-3.72" spread="1.43"/>
                    <measurement group_id="O3" value="-3.78" spread="1.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Visit 14 (Month 13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" spread="1.81"/>
                    <measurement group_id="O2" value="-3.73" spread="1.42"/>
                    <measurement group_id="O3" value="-3.77" spread="1.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Visit 15 (Month 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.77" spread="2.27"/>
                    <measurement group_id="O2" value="-3.71" spread="1.42"/>
                    <measurement group_id="O3" value="-3.78" spread="1.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Serum Testosterone Levels</title>
        <description>Percent change from Baseline in serum testosterone levels was measured.</description>
        <time_frame>Phase A Visit 1-8 and Phase B Visit 9-15.</time_frame>
        <population>Analysis set consist of Full Phase B analysis set, which comprised of patients who completed 7 months of treatment and had a PSA ≤2.0 ng/mL at the end of Month 7 and had at least one primary endpoint efficacy assessment after Month 7.</population>
        <group_list>
          <group group_id="O1">
            <title>DI (Degarelix Intermittent)</title>
            <description>Patients in this arm received degarelix with a starting dose of 240 mg at a concentration of 40 mg/mL on Day 0 (Visit 1) administered subcutaneously (s.c.) into the anterior abdominal wall via two equivalent injections of 120 mg (3 mL) each.
Six maintenance doses of degarelix 80 mg per month at a concentration of 20 mg/mL (4 mL) at Days 28 to 168 (Visit 2 through 7), administered s.c. into the anterior abdominal wall.
During Phase B of the trial, If a patient had Prostate Specific Antigen (PSA) ≥2 ng/mL at any visit, additional doses of degarelix 240 mg followed by 80 mg maintenance dose(s) were administered.
Degarelix: Degarelix treatment provided for first seven months (one starting dose and six maintenance doses) followed by no treatment for next seven months period.</description>
          </group>
          <group group_id="O2">
            <title>DC (Degarelix Continuous)</title>
            <description>Patients in this arm received degarelix with a starting dose of 240 mg at a concentration of 40 mg/mL administered on Day 0 (Visit 1) s.c. into the anterior abdominal wall via two equivalent injections of 120 mg (3 mL) each.
Thirteen maintenance doses of degarelix 80 mg per month at a concentration of 20 mg/mL (4 mL) at Days 28 to 364, administered s.c. into the anterior abdominal wall.
Degarelix: Degarelix treatment provided for complete study period (one starting dose and 13 maintenance doses).</description>
          </group>
          <group group_id="O3">
            <title>LC (Leuprolide Continuous)</title>
            <description>Patients in this arm received leuprolide 7.5 mg one-month depot injection on Day 0 (Visit 1), administered intramuscular (i.m.) into a large muscle, as per manufacturer’s labeling directions.
One injection of 22.5 mg leuprolide 3-month depot was administered i.m. into a large muscle, according to the directions for use in the manufacturer’s labeling at Day 28 and every 3 months afterwards for 4 additional doses (i.e at Days 112, 196, 280, and 364, respectively).
On Investigator’s discretion, patients in the arm could take bicalutamide (Casodex®) for a maximum of 28 days to alleviate increased signs and symptoms due to initial upsurge in testosterone levels.
Leuprolide: Leuprolide treatment for complete study period (one starting dose and 5 maintenance doses of 3-month depot each).</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Serum Testosterone Levels</title>
          <description>Percent change from Baseline in serum testosterone levels was measured.</description>
          <population>Analysis set consist of Full Phase B analysis set, which comprised of patients who completed 7 months of treatment and had a PSA ≤2.0 ng/mL at the end of Month 7 and had at least one primary endpoint efficacy assessment after Month 7.</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Phase A, Visit 1 (Day 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">This visit was the first dosing visit. Serum samples were collected pre-dosing on this visit. Thus, the estimated value obtained on this visit were considered as Baseline value. Hence no change is reported.</measurement>
                    <measurement group_id="O2" value="-95.8">One patient erroneously received medication prior to this visit. Thus, the value obtained on this visit was considered as first post-baseline value for this patient and is reported. There was no SD.</measurement>
                    <measurement group_id="O3" value="NA">This visit was the first dosing visit. Serum samples were collected pre-dosing on this visit. Thus, the estimated value obtained on this visit were considered as Baseline value. Hence no change is reported.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase A, Visit 2 (Month 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-96.4" spread="5.26"/>
                    <measurement group_id="O2" value="-97.4" spread="2.31"/>
                    <measurement group_id="O3" value="-95.5" spread="4.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase A, Visit 3 (Month 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-97.3" spread="2.46"/>
                    <measurement group_id="O2" value="-97.5" spread="1.9"/>
                    <measurement group_id="O3" value="-97.7" spread="1.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase A, Visit 4 (Month 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-97.5" spread="2.06"/>
                    <measurement group_id="O2" value="-97.8" spread="1.41"/>
                    <measurement group_id="O3" value="-97.5" spread="1.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase A, Visit 5 (Month 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-97.2" spread="4.26"/>
                    <measurement group_id="O2" value="-97.7" spread="1.58"/>
                    <measurement group_id="O3" value="-96.2" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase A, Visit 6 (Month 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-97.3" spread="4.42"/>
                    <measurement group_id="O2" value="-97.6" spread="2.49"/>
                    <measurement group_id="O3" value="-97.8" spread="1.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase A, Visit 7 (Month 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-96.8" spread="7.01"/>
                    <measurement group_id="O2" value="-97.6" spread="2.03"/>
                    <measurement group_id="O3" value="-97.9" spread="1.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase A, Visit 8 (Month 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-96.9" spread="6.34"/>
                    <measurement group_id="O2" value="-97.5" spread="2.54"/>
                    <measurement group_id="O3" value="-97.7" spread="1.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Visit 9 (Month 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-95.6" spread="9.69"/>
                    <measurement group_id="O2" value="-97.1" spread="3.09"/>
                    <measurement group_id="O3" value="-97.8" spread="1.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Visit 10 (Month 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-88.7" spread="24.7"/>
                    <measurement group_id="O2" value="-97" spread="3.14"/>
                    <measurement group_id="O3" value="-97.7" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Visit 11 (Month 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-77" spread="34.8"/>
                    <measurement group_id="O2" value="-97" spread="3.74"/>
                    <measurement group_id="O3" value="-97.5" spread="3.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Visit 12 (Month 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-65.4" spread="37.7"/>
                    <measurement group_id="O2" value="-96.7" spread="3.43"/>
                    <measurement group_id="O3" value="-97.9" spread="1.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Visit 13 (Month 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-54.7" spread="41.5"/>
                    <measurement group_id="O2" value="-96" spread="5.56"/>
                    <measurement group_id="O3" value="-97.8" spread="1.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Visit 14 (Month 13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-51.9" spread="43.1"/>
                    <measurement group_id="O2" value="-96.5" spread="3.7"/>
                    <measurement group_id="O3" value="-97.4" spread="4.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase B, Visit 15 (Month 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-44" spread="66.1"/>
                    <measurement group_id="O2" value="-95.8" spread="4.8"/>
                    <measurement group_id="O3" value="-97.7" spread="1.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>15 months</time_frame>
      <desc>Information related to AEs were collected throughout the trial from the time the subject signed the informed consent form till the end of the follow-up period.</desc>
      <group_list>
        <group group_id="E1">
          <title>DI (Degarelix Intermittent)</title>
          <description>Patients in this arm received degarelix with a starting dose of 240 mg at a concentration of 40 mg/mL on Day 0 (Visit 1) administered subcutaneously (s.c.) into the anterior abdominal wall via two equivalent injections of 120 mg (3 mL) each.
Six maintenance doses of degarelix 80 mg per month at a concentration of 20 mg/mL (4 mL) at Days 28 to 168 (Visit 2 through 7), administered s.c. into the anterior abdominal wall.
During Phase B of the trial, If a patient had Prostate Specific Antigen (PSA) ≥2 ng/mL at any visit, additional doses of degarelix 240 mg followed by 80 mg maintenance dose(s) were administered.
Degarelix: Degarelix treatment provided for first seven months (one starting dose and six maintenance doses) followed by no treatment for next seven months period.</description>
        </group>
        <group group_id="E2">
          <title>DC (Degarelix Continuous)</title>
          <description>Patients in this arm received degarelix with a starting dose of 240 mg at a concentration of 40 mg/mL administered on Day 0 (Visit 1) s.c. into the anterior abdominal wall via two equivalent injections of 120 mg (3 mL) each.
Thirteen maintenance doses of degarelix 80 mg per month at a concentration of 20 mg/mL (4 mL) at Days 28 to 364, administered s.c. into the anterior abdominal wall.
Degarelix: Degarelix treatment provided for complete study period (one starting dose and 13 maintenance doses).</description>
        </group>
        <group group_id="E3">
          <title>LC (Leuprolide Continuous)</title>
          <description>Patients in this arm received leuprolide 7.5 mg one-month depot injection on Day 0 (Visit 1), administered intramuscular (i.m.) into a large muscle, as per manufacturer’s labeling directions.
One injection of 22.5 mg leuprolide 3-month depot was administered i.m. into a large muscle, according to the directions for use in the manufacturer’s labeling at Day 28 and every 3 months afterwards for 4 additional doses (i.e at Days 112, 196, 280, and 364, respectively).
On Investigator’s discretion, patients in the arm could take bicalutamide (Casodex®) for a maximum of 28 days to alleviate increased signs and symptoms due to initial upsurge in testosterone levels.
Leuprolide: Leuprolide treatment for complete study period (one starting dose and 5 maintenance doses of 3-month depot each).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Myocardial ischemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Peptic ulcer hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Neutropenic infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute myeloid leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Bile duct cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Lung squamous cell carcinoma stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Neuroendocrine carcinoma of the skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Dementia alzheimer's type</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Transient ischemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Urethral stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Pulmonary edema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Pelvic venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Peripheral ischemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Subclavian steal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Venous insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="159" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="158" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="175"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="175"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="175"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="284" subjects_affected="79" subjects_at_risk="175"/>
                <counts group_id="E2" events="150" subjects_affected="29" subjects_at_risk="50"/>
                <counts group_id="E3" events="32" subjects_affected="19" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="41" subjects_affected="30" subjects_at_risk="175"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="50"/>
                <counts group_id="E3" events="32" subjects_affected="32" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="124" subjects_affected="42" subjects_at_risk="175"/>
                <counts group_id="E2" events="56" subjects_affected="17" subjects_at_risk="50"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" events="40" subjects_affected="23" subjects_at_risk="175"/>
                <counts group_id="E2" events="11" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Injection site oedema</sub_title>
                <counts group_id="E1" events="15" subjects_affected="6" subjects_at_risk="175"/>
                <counts group_id="E2" events="21" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="175"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" events="16" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="13" subjects_affected="6" subjects_at_risk="175"/>
                <counts group_id="E2" events="7" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E3" events="19" subjects_affected="13" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Nasophayrngitis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="175"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="175"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" events="13" subjects_affected="10" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="175"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="175"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="175"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E3" events="12" subjects_affected="10" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="175"/>
                <counts group_id="E2" events="10" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E3" events="27" subjects_affected="17" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="175"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E3" events="13" subjects_affected="10" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="18" subjects_affected="10" subjects_at_risk="175"/>
                <counts group_id="E2" events="9" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="175"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="14" subjects_affected="10" subjects_at_risk="175"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" events="10" subjects_affected="9" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="175"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="175"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="175"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="175"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" events="91" subjects_affected="87" subjects_at_risk="175"/>
                <counts group_id="E2" events="26" subjects_affected="26" subjects_at_risk="50"/>
                <counts group_id="E3" events="113" subjects_affected="110" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="175"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E3" events="19" subjects_affected="17" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Development Support</name_or_title>
      <organization>Ferring Pharmaceuticals</organization>
      <email>DK0-Disclosure@ferring.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

